Poster Presentations Session I

POSTER PRESENTATIONS SESSION I
SET-UP:	Monday May 18, 2009 - 7:30AM-8:00AM
POSTER DISPLAY HOURS:	Monday May 18, 2009 - 8:00AM-8:00PM
POSTER AUTHOR DISCUSSION HOUR:	Monday May 18, 2009 - 6:00PM-7:00PM
DISMANTLE:	Monday May 18, 2009 - 8:00PM-8:30PM

CONCEPTUAL PAPERS & RESEARCH ON METHODS Clinical Outcomes Methods
PMC1	CLASSIFYING PATIENTS WITH METABOLIC SYNDROME USING THE LATENT CLASS ANALYSIS (LCA)
	Liu G¹, Luo N², McCollam PL³
	¹Peking University, Beijing, China, ²National University of Singapore, Singapore, Singapore, ³Eli Lilly and Company, Indianapolis, IN, USA

PMC2	LONGITUDINAL DATA EXPLORATION WITH STACKED CUMULATIVE PERCENT PLOTS FOR CATEGORICAL DATA
	Gilligan TM, Hill CD
	RTI Health Solutions, Research Triangle Park, NC, USA

PMC3	USING FRONTIER ANALYSIS TO OPTIMIZE THE OVERALL LIFE YEARS GAINED IN VACCINATION POLICY OF INFECTIOUS DISEASES
	Chang CJ¹, Wu D², Lin YJ¹, Fann CS³
	¹Chang Gung University, Tao Yuan, Taiwan, ²National Yang-Ming University, Taipei, Taiwan, ³Academia Sinica, Taipei, Taiwan

PMC4	A FRAMEWORK FOR DEVELOPING A FLEXIBLE CONTROL-BASED ASTHMA POLICY MODEL
	Campbell JD¹, Hansen RN¹, Briggs A², Sullivan SD¹
	¹University of Washington, Seattle, WA, USA, ²University of Glasgow, Glasgow, UK

PMC5	PRO AND UTILITY ASSESSMENT: ADDRESSING CONFOUNDS OF CHANGING SELF-REFERENCE
	Pashko S
	Omnicare Clinical Research, King of Prussia, PA, USA

PMC6	META-REGRESSION AS A METHOD OF IDENTIFICATION OF THE CAUSES OF HETEROGENEITY BETWEEN STUDIES ON THE EXAMPLE OF RELATIONSHIP BETWEEN SURROGATES AND CLINICALLY IMPORTANT ENDPOINTS IN TYPE-2 DIABETES MELLITUS
	Marcisz A¹, Rys P², Wieczorek A¹, Plisko R², Wladysiuk M¹, Skrzekowska-Baran I³
	¹HTA Consulting, Krakow, Malopolska, Poland, ²HTA Consulting, Krakow, Poland, ³Novo Nordisk, Inc., Warsaw, Mazowieckie, Poland

PMC7	EFFECTS OF HETEROGENEITY ON THE ESTIMATION AND COMPARISON OF MEDICATION ERROR RATES
	de Moor C, Golembesky A
	PPD Inc, Morrisville, NC, USA

PMC8	SYSTEMATIC REVIEW RELIABILITY: EFFICACY OF TWO INDEPENDENT REVIEWERS AND TWO-STEP REVIEWS
	Pietri G, Muston D
	Heron Evidence Development Ltd, Stopsley, Luton, UK

PMC9	SIGNIFICANCE OF INCORPORATING COMMUNITY-BASED DATA OF A TARGET POPULATION INTO PHARMACOECONOMIC MODELS
	Farahani P
	Berkshire Medical Center, University of Massachusetts Medical School, Pittsfield, MA, USA

CONCEPTUAL PAPERS & RESEARCH ON METHODS Cost Methods

PMC10	COMPARISON BETWEEN PROPENSITY SCORE AND TRADITIONAL COVARIATE ADJUSTMENT WITH LOGISTIC REGRESSION MODELS IN ESTIMATING THE AVERAGE TREATMENT EFFECTS (ATES): RESULTS FROM MONTE CARLO SIMULATIONS
	Le QA, Hay JW
	University of Southern California, Los Angeles, CA, USA

PMC11	GROWTH, CHARACTERISTICS AND QUALITY OF THE COST-UTILITY ANALYSIS LITERATURE THROUGH 2006
	Greenberg D¹, Fang C¹, Cohen JT¹, Eldar-Lissai A², Neumann PJ¹
	¹Tufts-New England Medical Center, Boston, MA, USA, ²University of Rochester, Rochester, NY, USA

PMC12	VALIDATION OF HEALTH CARE RESOURCE USE QUESTIONNAIRES IN MEXICO
	Tenorio C¹, Vargas J², Ivanova S³, Martínez-Fonseca J³, Paladio Á³, Mould-Quevedo J⁴
	¹Instituto Nacional de Cancerología, Mexico, DF, Mexico, ²Econopharma Consulting SA de CV, Mexico, DF, Mexico, ³Econopharma Consulting SA de CV, Mexico City, Mexico, ⁴Pfizer Mexico, Mexico City, Mexico

PMC13	A QALY ALTERNATIVE FOR COST-EFFECTIVENESS ANALYSIS IN HEALTH CARE
	Gandjour A
	Rice University, Houston, TX, USA

PMC14	DETERMINING COSTS OF CONCOMITANT MEDICATIONS IN RANDOMIZED CLINICAL TRIALS: A CASE STUDY
	Han L¹, de Moor C², Whiteley M², McMillan C¹, Payne J¹, Naik J¹, Kelly S¹
	¹PPD Inc, Wilmington, NC, USA, ²PPD Inc, Morrisville, NC, USA

PMC15	EVALUATING AN ONLINE FREEWARE CALCULATOR FOR A COST EFFECTIVENESS MODEL TO ASSESS THE IMPACT OF MEDICATION COMPLIANCE
	McGhan WF, Willey VJ, Peterson AM, Manke AA, Patel DD, Ajmera MR
	University of the Sciences, Philadelphia, PA, USA

PMC16	EVALUATING AN ONLINE FREEWARE CALCULATOR AND PLOTTER FOR POWER ANALYSIS AND SAMPLE SIZE ESTIMATION FOR COST EFFECTIVENESS STUDIES
	McGhan WF, Willey VJ, Peterson AM
	University of the Sciences, Philadelphia, PA, USA

PMC17	WITHDRAWN

PMC18	WITHDRAWN

PMC19	COST-EFFECTIVENESS OF PREVENTIVE CARE AND MEDICINES: DO AGING DISEASES OFFSET SAVINGS FROM MORBIDITY REDUCTION?
	Gandjour A
	Rice University, Houston, TX, USA

PMC20	ESTIMATION OF HETEROGENOUS AVERAGE TREATMENT EFFECT OF BIOLOGIC DMARDS- PANEL DATA CORRELATED RANDOM COEFFICIENTS MODEL WITH POLYCHOTOMOUS ENDOGENOUS TREATMENT
	Kawatkar AA, Nichol MB
	University of Southern California, Los Angeles, CA, USA

PMC21	DOES VARYING SELECTION BIAS CORRECTION TECHNIQUE MATTER IN ESTIMATION OF TREATMENT EFFECTS IN PRESENCE OF MULTIPLE ENDOGENOUS TREATMENTS?
	Kawatkar AA, Nichol MB
	University of Southern California, Los Angeles, CA, USA

CONCEPTUAL PAPERS & RESEARCH ON METHODS Databases & Management Methods

PMC22	DIFFERENCE-IN-DIFFERENCE ANALYSIS IN THE EVALUATION OF AN INPATIENT INTERVENTION AMONG PATIENTS WITH COMMUNITY ACQUIRED PNEUMONIA
	An JJ, Knight TK, Wu J, Nichol MB
	University of Southern California, Los Angeles, CA, USA

PMC23	WHERE IS THE CURRENT FOCUS OF HEALTH ECONOMICS? AN INVESTIGATION INTO THE PUBLISHED LITERATURE WITHIN THREE KEY HEALTH ECONOMICS JOURNALS
	Samuels ER, Phiri D
	Heron Evidence Development Ltd, Luton, UK

PMC24	A PREDICTION MODEL TO IDENTIFY SUBJECTS WITH HORMONE REFRACTORY PROSTATE CANCER (HRPC) FROM A MANAGED CARE ADMINISTRATIVE CLAIMS DATABASE
	Alemayehu B¹, Buysman E², Parry D³, Nathan F¹
	¹AstraZeneca, Wilmington, DE, USA, ²i3 Innovus, Eden Prairie, MN, USA, ³AstraZeneca, Macclesfield, Cheshire, UK

PMC25	A SYSTEMATIC REVIEW OF BURDEN OF DISEASE STUDIES IN THE ASIA-PACIFIC REGION
	Zhao FL¹, Li SC²
	¹University of Newcastle, Newcastle, NSW, Australia, ²University of Newcastle, Callaghan, Australia

PMC26	USE OF HOSPITAL ELECTRONIC MEDICAL RECORD DATA TO DEFINE SEVERE SEPSIS, THE TIMING OF ORGAN DYSFUNCTION AND SOURCE OF INFECTION
	Emons MF¹, Yu HT¹, Haidar T², Xiong Y¹, Kramer AA¹, Khandker RK³, Spoeri RK¹
	¹Cerner LifeSciences, Beverly Hills, CA, USA, ²Cerner LifeSciences, Vienna, VA, USA, ³Wyeth Research, Collegeville, PA, USA

PMC27	VARIATION IN ICD-9 DIAGNOSIS CODING WITHIN AND ACROSS HEALTH SYSTEMS
	Moore KM¹, Andrade S², Cassidy-Bushrow A³, Dublin S⁴, Greenlee R⁵, Nakasato C⁶, Platt R¹, Raebel MM⁷, Rolnick C⁸, Smith DH⁹, Brown JS¹
	¹Harvard Medical School and Harvard Pilgrim Health Care, Boston, MA, USA, ²Meyers Primary Care Institute and Fallon Community Health Plan, Worcester, MA, USA, ³Henry Ford Hospital, Detroit, MI, USA, ⁴Group Health Center for Health Studies, Seattle, WA, USA, ⁵Marshfield Clinic Research Foundation, Marshfield, WI, USA, ⁶Kaiser Permanente Hawaii, Honolulu, HI, USA, ⁷Kaiser Permanente Colorado, Denver, CO, USA, ⁸HealthPartners Research Foundation, Minneapolis, MN, USA, ⁹Center for Health Research, Kaiser Permanente Northwest, Portland, OR, USA

PMC28	LINKAGE OF A MULTI-HOSPITAL DATABASE TO HEALTH PLAN CLAIMS DATA FOR CONTINUUM OF CARE OUTCOMES RESEARCH
	Ernst FR, Davis TE, Ryan AC, Stemkowski S
	Premier Inc, Charlotte, NC, USA

PMC29	DEVELOPMENT OF A REGULATORY POST-MARKETING STUDIES DATABASE
	Caron M¹, Mouchet J¹, Emery MP¹, Longin J², Maier WC³
	¹MAPI Research Trust, Lyon, France, ²MAPI, Lyon, France, ³MAPI-EPI, London, UK

PMC30	USING AN ENCOUNTER-BASED DATABASE TO VALIDATE A DISEASE PROGRESSION MODEL: LESSONS FOR MODELERS
	Klein TM, Wielage RC, Furiak NM, Klein RW
	Medical Decision Modeling, Inc, Indianapolis, IN, USA

PMC31	AN APPLICATION OF MULTINOMIAL LOGIT PROPENSITY SCORE MATCHING IN ADULT ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)
	Slaton T¹, Chaudhari P², Kozma C³
	¹Independent Consultant, West Columbia, SC, USA, ²Thomas Jefferson University, Philadelphia, PA, USA, ³Independent Consultant, St. Helena Island, SC, USA

PMC32	RELEVANCE OF CONFERENCE ABSTRACTS AND HAND-SEARCHING IN SYSTEMATIC REVIEWS
	Karia R, Zwaferink H, Malik MU
	Heron Evidence Development Ltd, Luton, UK

CONCEPTUAL PAPERS & RESEARCH ON METHODS Modeling Methods

PMC33	IMPACT OF IGNORING CORRELATION BETWEEN INPUT PARAMETERS ON VARIANCE OF COST-UTILITY RATIOS
	Kan HJ, Mukherjee J
	Bristol-Myers Squibb, Wallingford, CT, USA

PMC34	TOO MUCH ADO ABOUT INSTRUMENTAL VARIABLE APPROACH: IS THE CURE WORSE THAN THE DISEASE?
	Baser O
	University of Michigan and STATinMED Research, Ann Arbor, MI, USA

PMC35	USE OF CLASSIFICATION TREES AS AN AID IN UNDERSTANDING MISSING DATA: AN EXAMPLE FROM AN INTERNET-BASED SURVEY OF PATIENT CHARACTERISTICS AND RESOURCE UTILIZATION
	Zagar AJ¹, Khan SA², Hayes CP²
	¹Lilly USA, LLC, Indianapolis, IN, USA, ²Eli Lilly and Company, Indianapolis, IN, USA

PMC36	THE POPULATION IMPACT OF CHEMOTHERAPY IN LATE-STAGE PROSTATE CANCER: A SIMULATION STUDY USING TAX327 AND SEER-MEDICARE DATA
	Onukwugha E¹, Mullins CD¹, Seal B², Hussain A³
	¹University of Maryland School of Pharmacy, Baltimore, MD, USA, ²Sanofi-Aventis, Bridgewater, NJ, USA, ³University of Maryland School of Medicine, Baltimore, MD, USA

PMC37	COMPARISON OF PROPENSITY SCORE MATCHING AND USE OF INVERSE PROBABILITY OF TREATMENT WEIGHTS
	Cao Z¹, Durden ED², Mark TL²
	¹Thomson Reuters, Cambridge, MA, USA, ²Thomson Medstat, Cambridge, MA, USA, ²The Healthcare Business of Thomson Reuters, Washington, DC, USA

PMC38	VALIDATION OF THE IHE/J&J ECONOMIC SIMULATION MODEL OF TYPE-2 DIABETES MELLITUS (T2DM)
	Asseburg C¹, Willis M¹, Persson U¹, Neslusan C², He J²
	¹IHE - The Swedish Institute for Health Economics, Lund, Sweden, ²Johnson & Johnson Pharmaceutical Services LLC, Raritan, NJ, USA

PMC39	A TRANSMISSION-DYNAMIC MODEL TO PREDICT THE INDIRECT BENEFITS OF INFANT VACCINATION WITH 7-VALENT PNEUMOCOCCAL CONJUGATE VACCINE (PCV7) TO OLDER POPULATIONS
	Snedecor S¹, Strutton DR², Ciuryla V², Schwartz EJ³, Botteman M¹
	¹PharMerit North America LLC, Bethesda, MD, USA, ²Wyeth Research, Collegeville, PA, USA, ³Washington State University, Pullman, WA, USA

PMC40	METHODS FOR PERSONALIZED MEDICINE: FACTOR MIXTURE MODELS FOR INVESTIGATING DIFFERENTIAL RESPONSE TO TREATMENT
	Stull D¹, Wyrwich KW², Frueh FW³
	¹United BioSource Corporation, London, UK, ²United BioSource Corporation, Bethesda, MD, USA, ³Medco Health Solutions, Inc., Bethesda, MD, USA

PMC41	COMPARISON OF ANALYTIC APPROACHES TO ESTIMATE INCREMENTAL EXPENDITURES: A CASE OF OTITIS MEDIA AMONG CHILDREN IN THE UNITED STATES
	Kamble S¹, Bharmal M²
	¹University of North Carolina at Charlotte, Charlotte, NC, USA, ²Quintiles, Inc, Falls Church, VA, USA

PMC42	FINITE MIXTURE REGRESSIONS IN MODELING PRESCRIPTION DRUG UTILIZATION AND PRESCRIPTION DRUG EXPENDITURES OF PATIENTS WITH REUMATOID ARTHRITIS (RA)
	Kim J
	University of Utah, Salt Lake City, UT, USA

PMC43	INSTRUMENTAL VARIABLE APPROACH IN OUTCOMES RESEARCH
	Baser O¹, Dysinger A²
	¹University of Michigan and STATinMED Research, Ann Arbor, MI, USA, ²STATinMED Research, Ann Arbor, MI, USA

PMC44	DEVELOPMENT OF AN INTERACTIVE MODEL TO EVALUATE THE ECONOMIC IMPACT OF CHD EVENTS AMONG ADULTS WITH DYSLIPIDEMIA FROM AN EMPLOYER PERSPECTIVE
	Menzin J¹, Lang K¹, Zhang B¹, Korn JR¹, Simko RJ², Zachry WM³, Patel NV²
	¹Boston Health Economics, Inc, Waltham, MA, USA, ²Abbott Laboratories, Abbott Park, IL, USA, ³Abbott Laboratories, The Woodlands, TX, USA

PMC45	EXTENDING RANDOM EFFECT MODELS TO CENSORED COST DATA
	Baser O¹, Yuce H², Gust C³
	¹University of Michigan and STATinMED Research, Ann Arbor, MI, USA, ²STATinMED Research and The City University of New York, Brooklyn, NY, USA, ³STATinMED Research, Ann Arbor, MI, USA

PMC46	A REVIEW OF THE EVOLUTION OF HEALTH ECONOMIC MODELS OF SMOKING CESSATION
	Fisher MI¹, Muston D², Knight CJ¹
	¹Heron Evidence Development Ltd, Luton, UK, ²Heron Evidence Development Ltd, Stopsley, Luton, UK

PMC47	USE OF STABILIZED INVERSE PROPENSITY SCORES AS WEIGHTS TO DIRECTLY ESTIMATE RELATIVE RISK AND ITS CONFIDENCE INTERVALS
	Xu S¹, Ross C¹, Raebel MA¹, Shetterly S¹, Blanchette CM², Smith DH³
	¹Kaiser Permanente Colorado, Denver, CO, USA, ²Lovelace Respiratory Research Institute, Albuquerque, NM, USA, ³Center for Health Research, Kaiser Permanente Northwest, Portland, OR, USA

PMC48	“UNNATURAL” HISTORY: MODELING DISEASE PROGRESSION USING OBSERVATIONAL DATA
	Noyes K¹, Bajorska A¹, Chappel AR², Schwid S¹, Mehta LR², Holloway R¹, Dick A³
	¹University of Rochester School of Medicine, Rochester, NY, USA, ²University of Rochester, Rochester, NY, USA, ³The RAND Corporation, Pittsburgh, PA, USA

PMC49	A FACTORIAL SIMULATION OF THE GAINS FROM AN EMPIRICAL BAYES APPROACH OVER CLASSICAL METHODS
	Murray JF¹, Fryback DG²
	¹Eli Lilly and Company, Indianapolis, IN, USA, ²University of Wisconsin-Madison, Madison, WI, USA

PMC50	REGRESSION ESTIMATORS FOR QUALITY OF LIFE AND QUALITY-ADJUSTED LIFE YEARS (QALYS)
	Basu A¹, Manca A²
	¹University of Chicago, Chicago, IL, USA, ²University of York, York, UK

CONCEPTUAL PAPERS & RESEARCH ON METHODS Patient-Reported Outcomes Studies

PMC51	TESTING THE ROLE OF TIME IN AFFECTING THE UNIDIMENSIONALITY IN EQ-5D USING THE 2002-2003 MEDICAL EXPENDITURE PANEL SURVEY (MEPS): A FACETS MODEL APPROACH
	Gu NY, Doctor JN
	University of Southern California, Los Angeles, CA, USA

PMC52	CULTURAL ADAPTATION AND VALIDATION OF A HEATH RELATED QUALITY OF LIFE QUESTIONNAIRE : FUNCTIONAL OUTCOMES OF SLEEP QUESTIONNAIRE
	Malhan S¹, Oksuz E¹, Tulunay FC²
	¹Baskent University, Ankara, Turkey, ²Ankara University, Ankara, Turkey

PMC53	SHOULD AN SF-10 REPLACE THE SF-12?
	Gu NY, Doctor JN
	University of Southern California, Los Angeles, CA, USA

PMC54	ARE YOUNG CHILDREN ABLE TO MAKE TRADE-OFFS? A QUALITATIVE STUDY OF CHILDREN AGED 6 TO 12 YEARS AND THEIR PERCEPTIONS OF INFLUENZA VACCINATION
	Flood E¹, Rousculp MD², Sasane M¹, Toback S², Divino V³, Mahadevia PJ², Beusterien KM¹
	¹Oxford Outcomes, Bethesda, MD, USA, ²MedImmune, Inc., Gaithersburg, MD, USA, ³Oxford Outcomes, Gaithersburg, MD, USA

PMC55	IMPACT OF THE FDA DRAFT GUIDANCE ON PATIENT REPORTED OUTCOMES (PRO) LABEL CLAIMS FOR APPROVED DRUG PRODUCTS IN THE US: HAS IT MADE A DIFFERENCE?
	Mordin M¹, Clark M¹, Siersma C¹, Copley-Merriman K¹, Gnanasakthy A²
	¹RTI Health Solutions, Ann Arbor, MI, USA, ²Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA

PMC56	THE EFFECT OF RECALL PERIOD ON CANCER PATIENTS' RATINGS OF THE SEVERITY OF MULTIPLE SYMPTOMS
	Shi Q¹, Trask PC², Wang S¹, Mendoza T¹, Cleeland C¹
	¹University of Texas M. D. Anderson Cancer Center, Houston, TX, USA, ²Pfizer, New London, CT, USA

PMC57	RELATIONSHIP BETWEEN QUALITY OF LIFE AND HEALTH-RELATED MEASURES INCLUDING SYMPTOMS, BIOCHEMICAL MARKERS AND TUMOR BURDEN.
	Vinik EJ, Vinik AI, Silva MP
	Eastern Virginia Medical School, Norfolk, VA, USA

PMC58	TEST-RETEST RELIABILITY OF THE EQ-5D VISUAL ANALOG SCALE ACROSS POPULATIONS AND CONDITIONS
	Wilke CT¹, Pickard AS²
	¹University of Illinois at Chicago, Chicago, IL, USA, ²College of Pharmacy, University of Illinois at Chicago, Chicago, IL, USA

PMC59	PSYCHOMETRIC ASSESSMENT OF AN INSTRUMENT TO MEASURE PATIENT SATISFACTION WITH MEDICATION THERAPY MANAGEMENT SERVICES
	Bodhani A¹, West D², Li C¹, Ounpraseuth S¹, Pace A¹
	¹University of Arkansas for Medical Sciences, Little Rock, AR, USA, ²University of Mississippi School of Pharmacy, University, MS, USA

PMC60	DETERMINING THE MINIMALLY IMPORTANT DIFFERENCES OF FOUR PREFERENCE-BASED HEALTH INDICES: A SIMULATION APPROACH
	Luo N¹, Johnson JA², Coons SJ³
	¹National University of Singapore, Singapore, Singapore, ²University of Alberta, Edmonton, AB, Canada, ³University of Arizona, Tucson, AZ, USA

PMC61	MEASURING POPULATION HEALTH STATUS USING EQ-5D: RESULTS FROM THE HEALTH SURVEY FOR ENGLAND 1996-2006
	Zarate V¹, Kind P²
	¹University of York, York, North Yorkshire, UK, ²University of York, York, UK

PMC62	ASSESSING THE QUALITY OF CONJOINT ANALYSIS APPLICATIONS IN HEALTH: A PILOT EVALUATION OF THE ISPOR CHECKLIST FOR GOOD RESEARCH PRACTICE IN CONJOINT ANALYSIS
	Marshall DA¹, Hauber AB², Bridges JF³, Cameron R⁴, Weaver L², Dionne J⁴, Johnson FR²
	¹University of Calgary, Calgary, AB, Canada, ²RTI Health Solutions, Research Triangle Park, NC, USA, ³Johns Hopkins University, Bloomberg School of Public Health, Baltimore, MD, USA, ⁴McMaster University, Hamilton, ON, Canada

PMC63	THE TRANSLATION AND LINGUISTIC VALIDATION OF THE NEUROPATHY TOTAL SYMPTOM SCORE-6 SELF-ASSESSED VERSION (NTSS-6 SA)
	Furtado T, Gordon-Stables R, Wild D
	Oxford Outcomes Ltd, Oxford, UK

PMC64	DEVELOPMENT OF A CHECKLIST TO ASSESS THE QUALITY OF TRANSLATIONS OF PATIENT-REPORTED OUTCOMES (PRO) INSTRUMENTS
	Conway K¹, Acquadro C²
	¹MAPI Research Trust, Lyon, France, ²Hopital Saint-Louis, Paris, France

PMC65	A NOVEL COMPARISON OF QUALITATIVE DATA SOURCES: CONTENT ANALYSIS OF SEMI - STRUCTURED PATIENT INTERVIEWS VERSUS WEBLOGS (BLOGS)
	Acaster SL¹, Wild D²
	¹Oxford Outcomes, Oxford, UK, ²Oxford Outcomes Ltd, Oxford, UK

PMC66	USE OF THE MINI INTERNATIONAL NEUROPSYCHIATRIC INTERVIEW (M.I.N.I.) – VERSION 6 – IN AN INTERNATIONAL STUDY
	Boudrot A¹, D'uva F², Sheehan D³, Lecrubier Y⁴, Even C⁴
	¹Mapi Research Institute, Lyon, France, ²Mapi Research Institute, LYON, France, ³University of South Florida, Tampa, FL, USA, ⁴Centre Hospitalier Sainte-Anne, Paris, France

PMC67	THE TRANSLATION AND LINGUISTIC VALIDATION OF THE SUBJECTIVE WELL-BEING UNDER NEUROLEPTICS – SHORT VERSION (SWN-S) QUESTIONNAIRE
	Houchin C¹, Furtado T¹, Wild D¹, Naber D²
	¹Oxford Outcomes Ltd, Oxford, UK, ²University of Hamburg, Hamburg, Germany

PMC68	WITHDRAWN



PMC69	MULTITRAIT-MULTIMETHOD ANALYSIS OF THREE GENERIC PREFERENCE-BASED HEALTH-RELATED QUALITY OF LIFE MEASURES IN THE NATIONAL HEALTH MEASUREMENT STUDY
	Maglinte GA¹, Hays RD², Kaplan RM²
	¹UCLA, Woodland Hills, CA, USA, ²UCLA, Los Angeles, CA, USA

PMC70	VALUING HEALTH FROM SCRATCH: THE APPLICATION OF COMMONSENSE PRINCIPLES TO THE DESIGN OF HEALTH STATE VALUATION METHODS
	Kind P
	University of York, York, UK

PMC71	APPLICATION AND FURTHER VALIDATION OF A PATIENT-REPORTED OUTCOME INSTRUMENT: PATIENT SATISFACTION WITH PHARMACEUTICAL CARE QUESTIONNAIRE
	Chaudhari PK
	Thomas Jefferson University, Philadelphia, PA, USA

PMC72	ASSESSING ANXIETY AND DEPRESSION ON AN INTERNATIONAL LEVEL
	Neewoor S¹, D'uva F¹, Le Halpère A², Kroenke K³, Engels DJ⁴
	¹Mapi Research Institute, LYON, France, ²Sanofi-Aventis, Antony, France, ³Regenstrief Institute for Health Care, Indianapolis, IN, USA, ⁴Pfizer, New York, NY, USA

PMC73	EVALUATION OF GLP-1 PRODUCT ATTRIBUTES IN TREATING PEOPLE WITH TYPE-2 DIABETES IN US: COMPARING TIME-TRADEOFF AND WILLINGNESS-TO-PAY METHODOLOGIES
	Zanutto E¹, Conner C², Polster M³, McDonald SS¹, Hammer M⁴
	¹National Analysts Worldwide, Philadelphia, PA, USA, ²Novo Nordisk, Inc., Princeton, NJ, USA, ³National Analysts Worldwide, Philadelphia, PA, USA, ⁴Novo Nordisk A/S, Bagsværd, Denmark

PMC74	QUALITY-ADJUSTED LIFE YEARS SAVED BY PREVENTION OF HEAD INJURY THROUGH ENFORCEMENT OF HELMET LAW
	Lee HY¹, Chen YH², Wang JD³
	¹National Taiwan University Hospital, Taipei, Taiwan, ²University of Michigan, Ann Arbor, MI, USA, ³National Taiwan University, College of Public Health, Taipei, Taiwan

PMC75	MEANINGFUL VERSUS USEABLE RESPONSES TO PREFERENCE SURVEYS: INSIGHTS INTO IMPROVING THE VALIDITY OF HEALTH UTILITY SCORES
	Wittenberg E¹, Prosser LA²
	¹Brandeis University, Waltham, MA, USA, ²University of Michigan, Ann Arbor, MI, USA

PMC76	AN ASSESSMENT OF THE EVIDENCE TO SUPPORT THE USE OF LINGUISTIC VALIDATION INTERVIEWS AS AN INTEGRAL PART OF THE TRANSLATION OF PROS FOR USE IN MULTI-NATIONAL TRIALS
	Gordon-Stables R, Houchin C, Wild D
	Oxford Outcomes Ltd, Oxford, UK

PMC77	DEVELOPMENT AND VALIDATION OF AN E-PRO TEMPLATE ADMINISTERED VIA A WEB-BASED INTERFACE
	Eremenco S¹, Coyne KS¹, Duran B², Leidy NK¹
	¹United BioSource Corporation, Bethesda, MD, USA, ²United BioSource Corporation, Lexington, MA, USA

PMC78	WITHDRAWN



PMC79	TRANSLATION OF THE PATIENT-REPORTED OUTCOMES MEASUREMENT INFORMATION SYSTEM INTO SPANISH
	Arnold BJ, Correia H, Cella D
	NorthShore University HealthSystem, Evanston, IL, USA

PMC80	WITHDRAWN



PMC81	ELECTRONIC PATIENT REPORTED OUTCOMES: FOLLOWING FDA GUIDANCE FROM A VENDOR PERSPECTIVE
	Ross J, Shea E
	Almac Clinical Technologies, Yardley, PA, USA

PMC82	PSYCHOMETRIC PROPERTIES OF FOUR KISWAHILI TRANSLATED DISEASE SPECIFIC PATIENT REPORTED OUTCOME MEASURES
	Kangethe AW, Franic DM
	University of Georgia, Athens, GA, USA

PMC83	USE OF CONJOINT ANALYSIS IN HEALTH OUTCOMES RESEARCH: AN EXAMINATION OF THE LITERATURE
	Szeinbach SL, Beyer AP, Qureshi ZP, Uhas AA, Visaria J, Seoane-Vazquez E
	Ohio State University, Columbus, OH, USA

PMC84	THE POWER OF ASSUMPTIONS
	van Hout BA
	Pharmerit Ltd, York, North Yorkshire, UK

PMC85	THE TRANSLATION AND LINGUISTIC VALIDATION OF THE PAR-ENT-QOL QUESTIONNAIRE
	Houchin C¹, Taieb C², Wild D¹
	¹Oxford Outcomes Ltd, Oxford, UK, ²Pierre Fabre, Boulogne, France

PMC86	THE IMPACT OF DISEASE ADAPTATION ON GENERAL POPULATION VALUES
	McTaggart-Cowan HM, Tsuchiya A, O'Cathain A, Brazier JE
	University of Sheffield, Sheffield, South Yorkshire, UK

CONCEPTUAL PAPERS & RESEARCH ON METHODSStudy Design

PMC87	COMPARING CHART REVIEW AND MODIFIED DELPHI PANEL RESOURCE DATA COLLECTION METHODS: THE COST OF TREATMENT FOR MULTIPLE MYELOMA IN SWEDEN
	Ghatnekar O¹, Liwing J², Löthgren M², Aschan J², Mellqvist UH³, Persson S¹
	¹The Swedish Institute for Health Economics, Lund, Sweden, ²Janssen-Cilag AB, Sollentuna, Sweden, ³Sahlgrenska University Hospital, Gothenburg, Sweden

PMC88	AN EXPLORATORY ANALYSIS OF REASONS BEHIND PREMATURE TERMINATION OF RANDOMIZED CONTROLLED TRIALS
	Dimri S, Ubhadiya BS, Singh N, Narvilkar P, Bhanderi M
	Heron Health Private Limited, Chandigarh, India

PMC89	WITHDRAWN

PMC90	MANAGING STUDY PARTICIPANT RECRUITMENT SITES: METHODS FOR OPTIMIZING SUBJECT RECRUITMENT AND RETENTION THROUGH PRIVATE PRACTICE OFFICES
	Schoenberger C, Ruetsch C
	Health Analytics, LLC, Columbia, MD, USA

PMC91	REPORTING QUALITY OF DOUBLE-BLIND RANDOMIZED CONTROLLED TRIALS AND ITS ASSOCIATION WITH THE FUNDING AGENCY
	Singh N, Agrawal R, Dimri S, Ubhadiya BS, Narvilkar P, Bhanderi M
	Heron Health Private Limited, Chandigarh, India

POSTER PRESENTATIONS SESSION I
SET-UP:	Monday May 18, 2009 - 7:30AM-8:00AM
POSTER DISPLAY HOURS:	Monday May 18, 2009 - 8:00AM-8:00PM
POSTER AUTHOR DISCUSSION HOUR:	Monday May 18, 2009 - 6:00PM-7:00PM
DISMANTLE:	Monday May 18, 2009 - 8:00PM-8:30PM

CANCER Clinical Outcomes Studies
PCN1	TIME DELAY OF OCCURRENCE OF SECONDARY MALIGNANT TUMORS AFTER PRIMARY BREAST CANCER IN THE FEMALE POPULATION OF HUNGARY BETWEEN 2003 AND 2007
	Gazdag L¹, Boncz I¹, Farkasné JE¹, Bódis J², Németh K¹, Kornya L¹, Vránics I¹, Gabara K¹, Kriszbacher I²
	¹University of Pécs, Pécs, Hungary, ²University of Pécs, Pecs, Hungary

PCN2	THE FREQUENCY OF OCCURRENCE OF SECONDARY MALIGNANT TUMORS EVOLVING ON THE FIELD OF PRIMARY BREAST CANCER IN THE FEMALE POPULATION OF HUNGARY BETWEEN 2003 AND 2007
	Gazdag L¹, Boncz I¹, Farkasné JE¹, Bódis J², Németh K¹, Kornya L¹, Vránics I¹, Gabara K¹, Kriszbacher I²
	¹University of Pécs, Pécs, Hungary, ²University of Pécs, Pecs, Hungary

PCN3	THE FEASIBILITY AND COST OF EARLY DETECTION OF PROSTATE CANCER IN GASTROENTEROLOGY UNITS
	Shafran-Tikva S¹, Lysy J¹, Goldin E¹, Greenberg D²
	¹Hadassah University Medical Center, Ein Kerem, Jerusalem, Israel, ²Ben-Gurion University of the Negev, Beer-Sheva, Israel

PCN4	WITHDRAWN

PCN5	GAINS ASSOCIATED WITH CLINICAL EXAMS AND MAMMOGRAPHIC SCREENING FOR WOMEN ABOVE 40 YEARS OF AGE
	Caleffi M¹, Boscatti FHG², Ribeiro RA¹, Bedin Junior A¹, Duarte Filho D¹, Muranaka AH³, Weber B¹
	¹Hospital Moinhos de Vento, Porto Alegre, RS, Brazil, ²Universidade de São Paulo, Sao Paulo, SP, Brazil, ³Universidade Federal de São Paulo, Sao Paulo, SP, Brazil

PCN6	USING PREDICTIVE MODELS TO ANALYZE LUNG CANCER DATA
	Tang G
	University of Louisville, Louisville, KY, USA

PCN7	CLINICAL AND ECONOMIC OUTCOMES IN CANCER CHEMOTHERAPY PATIENTS INITIATED ON ERYTHROPOIESIS STIMULATING AGENTS (ESA) AT HEMOGLOBIN (HB) LEVELS <10 G/DL
	Burton T¹, Larholt K¹, Apgar E¹, Pashos CL¹, McKenzie RS², Piech CT²
	¹Abt Bio-Pharma Solutions, Inc., Lexington, MA, USA, ²Centocor Ortho Biotech Services, LLC, Horsham, PA, USA

PCN8	COMPARISON OF INFECTION-RELATED HOSPITALIZATION RISK AND ASSOCIATED COSTS AMONG PATIENTS RECEIVING SARGRAMOSTIM, FILGRASTIM, AND PEGFILGRASTIM FOR CHEMOTHERAPY-INDUCED NEUTROPENIA
	Duh MS¹, Toy EL², Vekeman F³, Laliberte F³, Dority BL², Perlman D², Barghout V⁴, Heaney ML⁵
	¹Analysis Group, Inc., Boston, MA, USA, ²Analysis Group, Inc., Lakewood, CO, USA, ³Groupe d'analyse, Ltee, Montréal, QC, Canada, ⁴Bayer HealthCare Pharmaceuticals, Inc., Wayne, NJ, USA, ⁵Memorial Sloan-Kettering Cancer Center, New York, NY, USA

PCN9	SYSTEMATIC LITERATURE REVIEW TO ADDRESS BREAST CANCER ISSUES IN LOW-AND MIDDLE-INCOMES COUNTRIES FROM 1990—2008
	Ekwueme DU¹, Coughlin SS², Miller J¹, Bobo J³, Justen E⁴
	¹CDC, Atlanta, GA, USA, ²Department of Veterans Affairs, Washington, DC, DC, USA, ³Battelle, Centers for Public Health Research and Evaluation, Seattle, WA, USA, ⁴CDC Foundation, Atlanta, GA, USA

PCN10	LUNG CANCER IN THE CHINESE PASSIVE SMOKING POPULATIONS
	Wang L¹, Li Y²
	¹Sichuan University, Chengdu, Sichuan, China, ²West China Hospital, Sichuan University, Chengdu, China

PCN11	LUNG CANCER IN THE CHINESE SMOKING POPULATION
	Wang L¹, Li Y²
	¹Sichuan University, Chengdu, Sichuan, China, ²West China Hospital, Sichuan University, Chengdu, China

PCN12	TIMING OF PHYSICIAN VISITS AND THE IMPACT ON SURVIVAL AMONG SEER-MEDICARE PATIENTS WITH STAGE IV PROSTATE CANCER
	Onukwugha E¹, Mullins CD¹, Seal B², Hussain A³
	¹University of Maryland School of Pharmacy, Baltimore, MD, USA, ²Sanofi-Aventis, Bridgewater, NJ, USA, ³University of Maryland School of Medicine, Baltimore, MD, USA

PCN13	THE PREVALENCE AND COSTS OF ADVERSE METABOLIC EFFECTS OF ATYPICAL ANTIPSYCHOTICS IN SCHIZOPHRENIC PATIENTS
	Su HC
	Chi-Mei Medical Center, tainan, Taiwan

PCN14	FFECTIVENESS ANALYSIS OF CHEMOTHERAPY PLUS CETUXIMAB COMPARED WITH CHEMOTHERAPY ALONE IN THE TREATMENT OF METASTATIC COLORECTAL CANCER IN TAIWAN
	Huang SF¹, Chan AL²
	¹Chi-Mei Medical Center, Tainan, Taiwan, ²Chi-Mei Medical center, Tainan, Taiwan

PCN15	ENDOMETRIAL CARCINOMA RISK OF VAGINAL ESTROGEN IN MEDICAID WOMEN WITH ATROPHIC VAGINITIS
	Neidecker MV¹, Camacho F², Balkrishnan R¹
	¹Ohio State University, Columbus, OH, USA, ²Penn State College of Medicine, Hershey, PA, USA

PCN16	COST OF MANAGING SIDE EFFECTS OF FIRST-LINE BEVACIZUMAB (BEV) + LOWER-DOSE INTERFERON-ALPHA2A IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (MRCC) IN GERMANY, FRANCE, AND UNITED KINGDOM
	Mickisch GH¹, Escudier B², Gore M³, Walzer S⁴, Nuijten MJ⁵
	¹Center of Operative Urology Bremen, Bremen, Germany, ²Institut Gustave Roussy, Villejuif, France, ³The Royal Marsden Hospital, London, UK, ⁴F. Hoffmann-La Roche Pharmaceuticals AG, Basel, Switzerland, ⁵Ars Accessus Medica, Jisp, Netherlands

PCN17	COST OF MANAGING SIDE EFFECTS OF FIRST-LINE THERAPY FOR METASTATIC RENAL CELL CARCINOMA (MRCC) IN GERMANY, FRANCE, UK AND ITALY: BEVACIZUMAB (BEV) + INTERFERON-ALPHA2A COMPARED WITH SUNITINIB
	Mickisch GH¹, Escudier B², Gore M³, Procopio G⁴, Walzer S⁵, Nuijten MJ⁶
	¹Center of Operative Urology Bremen, Bremen, Germany, ²Institut Gustave Roussy, Villejuif, France, ³The Royal Marsden Hospital, London, UK, ⁴Fondazione IRCCS “Istituto Nazionale dei Tumouri“, Milan, Italy, ⁵F. Hoffmann-La Roche Pharmaceuticals AG, Basel, Switzerland, ⁶Ars Accessus Medica, Jisp, Netherlands

PCN18	ECONOMIC IMPACT OF SEVERE INFUSION REACTIONS IN PATIENTS WITH COLORECTAL CANCER TREATED WITH CETUXIMAB
	Foley KA¹, Wang PF², Barber B², Long SR³, Bagalman JE⁴, Zhao Z²
	¹Thomas Jefferson University, Philadelphia, PA, USA, ²Amgen, Inc., Thousand Oaks, CA, USA, ³Thomson Reuters, Hampden, ME, USA, ⁴Thomson Reuters, WASHINGTON, DC, USA

CANCERCost Studies
PCN19	BUDGET IMPACT ANALYSIS OF SARGRAMOSTIM USE IN PATIENTS WITH CHEMOTHERAPY-INDUCED NEUTROPENIA
	Toy EL¹, Porter CL¹, Books P¹, Vekeman F², Barghout V³, Duh M⁴, Skarin AT⁵
	¹Analysis Group, Inc., Lakewood, CO, USA, ²Groupe d'analyse, Ltee, Montréal, QC, Canada, ³Bayer HealthCare Pharmaceuticals, Inc., Wayne, NJ, USA, ⁴Analysis Group, Inc., Boston, MA, USA, ⁵Dana-Farber Cancer Institute, Boston, MA, USA

PCN20	THE BUDGETARY IMPACT OF PEMETREXED PLUS CISPLATIN AS FIRST-LINE THERAPY FOR ADVANCED NONSQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC)
	Wielage RC¹, Muehlenbein CE², Liepa AM², Babineaux SM², Klein RW¹, Schwartzberg LS³
	¹Medical Decision Modeling, Inc, Indianapolis, IN, USA, ²Eli Lilly and Company, Indianapolis, IN, USA, ³The West Clinic, Memphis, TN, USA

PCN21	BUDGET IMPACT ANALYSIS OF NON - SMALL CELL LUNG CARCINOMA (NSCLC) TREATMENT WITH ERLOTINIB IN POLISH SETTING
	Orlewska E¹, Szczesna A², Szkultecka-Debek M³
	¹Centrum Farmakoekonomiki, Warsaw, Poland, ²Regional Lung Diseases Hospital, Otwock, Poland, ³Roche Polska, Warsaw, Poland

PCN22	PHARMACOECONOMIC APPLICATIONS IN FORMULARY MANAGEMENT: BUDGET IMPACT ANALYSIS OF CLORFARABINE AT A MAJOR CANCER CENTER
	Miller LA, Lau J, Lal LS, Arbuckle R
	University of Texas M.D. Anderson Cancer Center, Houston, TX, USA

PCN23	BUDGET IMPACT ANALYSIS OF DOCETAXEL REIMBURSEMENT IN INDUCTION THERAPY OF LOCALLY ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA IN POLAND
	Walczak J¹, Lasota K¹, Malczak I¹, Pawlik D¹, Semeniuk A¹, Simon A¹, Bryl M¹, Gierczynski J², Nogas G¹
	¹Arcana Institute, Cracow, Poland, ²Sanofi-Aventis sp. z o.o, Warszawa, Poland

PCN24	THE ECONOMIC IMPLICATIONS OF RASBURICASE TREATMENT IN ADULT TUMOR LYSIS SYNDROME PATIENTS
	Eaddy M¹, Seal B², Tangirala M³, O'Day K¹
	¹Xcenda, Palm Harbor, FL, USA, ²Sanofi-Aventis, Bridgewater, NJ, USA, ³Smith Hanley Consulting Group LLC, Lake Mary, FL, USA

PCN25	DRUG UTILIZATION AND COSTS FOR ERYTHROPOIESIS STIMULATING AGENTS (ESA) IN PATIENTS WITH BREAST, LUNG, OR GASTROINTESTINAL CANCER RECEIVING CHEMOTHERAPY
	Lafeuille MH¹, McKenzie RS², Vekeman F³, Bailey R², Piech CT², Lefebvre P¹
	¹Groupe d'analyse, Ltee, Montreal, QC, Canada, ²Centocor Ortho Biotech Services, LLC, Horsham, PA, USA, ³Groupe d'analyse, Ltee, Montréal, QC, Canada

PCN26	COMPARISON OF EPOETIN ALFA AND DARBEPOETIN ALFA DOSING PATTERNS AND COSTS IN CANCER INPATIENTS RECEIVING CHEMOTHERAPY
	Vekeman F¹, Bailey R², Lafeuille MH³, McKenzie RS², Herrera AD², Lefebvre P³
	¹Groupe d'analyse, Ltee, Montréal, QC, Canada, ²Centocor Ortho Biotech Services, LLC, Horsham, PA, USA, ³Groupe d'analyse, Ltee, Montreal, QC, Canada

PCN27	COMPARING AND VALIDATING DIFFERENT TYPES OF PROPENSITY SCORE MATCHING TECHNIQUES
	Baser O¹, Gust C², Akin C¹
	¹University of Michigan and STATinMED Research, Ann Arbor, MI, USA, ²STATinMED Research, Ann Arbor, MI, USA

PCN28	RETROSPECTIVE CLAIMS DATABASE ANALYSIS OF THE DIRECT MEDICAL COSTS ASSOCIATED WITH SORAFENIB AND SUNITINIB IN THE TREATMENT OF PATIENTS WITH RENAL CELL CARCINOMA WHO ARE UNDER 65 YEARS OLD
	Quinn DI¹, Barghout V², Moyneur E³
	¹University of Southern California, Los Angeles, CA, USA, ²Bayer HealthCare Pharmaceuticals, Inc., Wayne, NJ, USA, ³StatLog Consulting Inc, L'Ange-Gardien, QC, Canada

PCN29	THE COST SAVINGS ASSOCIATED WITH BEVACIZUMAB PLUS CISPLATIN AND GEMCITABINE (BEVACIZUMAB-BASED THERAPY) TREATMENT COMPARED WITH CETUXIMAB PLUS VINORELBINE AND CISPLATIN (CETUXIMAB-BASED THERAPY) IN PATIENTS WITH ADVANCED OR RECURRENT NON-SMALL CELL CANCER (NSCLC) ACROSS FOUR EUROPEAN COUNTRIES
	Nuijten M¹, Chouaid C², Vergnenegre A³
	¹Ars Accessus Medica, Jisp, Netherlands, ²Hôpital Saint-Antoine, Paris, France, ³CHU Limoges, Limoges, France

PCN30	THE COSTS OF TREATING PATIENTS WITH ADVANCED OR RECURRENT NON-SMALL CELL CANCER (NSCLC) WITH BEVACIZUMAB PLUS CISPLATIN AND GEMCITABINE COMPARED WITH PEMETREXED PLUS CISPLATIN IN INDUCTION AND MAINTENANCE THERAPY IN GERMANY AND ITALY
	Nuijten M
	Ars Accessus Medica, Jisp, Netherlands

PCN31	COST OF CARE FOR MEDICARE PATIENTS DIAGNOSED WITH METASTATIC BREAST CANCER WHO RECEIVED TRASTUZUMAB
	Doan J¹, Griffiths RI², Lalla D¹, Herbert R², Brammer M¹, Danese MD²
	¹Genentech, Inc., South San Francisco, CA, USA, ²Outcomes Insights, Inc, Newbury Park, CA, USA

PCN32	ECONOMIC EVALUATION OF SUNITINIB, SORAFENIB, BEVACIZUMAB/INTERFERON ALPHA AND TEMSIROLIMUS IN FIRST LINE TREATMENT OF METASTATIC RENAL CELL CARCINOMA IN ISRAEL
	Greenberg D
	Ben-Gurion University of the Negev, Beer-Sheva, Israel

PCN33	COST-EFFECTIVENESS ANALYSIS OF SORAFENIB ASSOCIATED TO BEST SUPPORTIVE CARE (BSC) VERSUS BEST SUPPORTIVE CARE ALONE IN THE SECOND LINE TREATMENT OF ADVANCED RENAL CELL CARCINOMA UNDER THE BRAZILIAN PUBLIC HEALTH CARE SYSTEM PERSPECTIVE
	Teich V¹, Fernandes RA¹, Schiola A²
	¹MedInsight, Rio de Janeiro, Brazil, ²Bayer Schering Pharma Brazil, São Paulo, Brazil

PCN34	ECONOMIC EVALUATION OF TEMOZOLOMIDE FOR THE TREATMENT OF NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME IN MEXICO
	Rely K¹, Salinas EG², Pierre KA³
	¹Network on the Economic Evaluation of Healthcare Programmes and its Applications to Decision Making in Latin American Countries, Mexico, DF, Mexico, ²Hospital Infantil de México Federico Gómez, Mexico, DF, Mexico, ³Johns Hopkins University, Bloomberg School of Public Health, Baltimore , MD, MD, USA

PCN35	COST-EFFECTIVENESS OF HUMAN PAPILLOMAVIRUS VACCINE IN COLOMBIA IN 2007
	de La Hoz F¹, Alvis N², Narváez J¹, Gamboa O³, Chocontá A¹
	¹Universidad Nacional de Colombia, Bogotá D.C, Colombia, ²Universidad de Cartagena, Cartagena, Colombia, ³Instituto Nacional de Cancerología, Bogotá D.C, Colombia

PCN36	THE ESTIMATED IMPACT OF IN VITRO BIOMARKERS ON THE COST-EFFECTIVENESS OF POPULATION-WIDE COLORECTAL CANCER SCREENING
	Wittenberg GM, Noy K, Dejori M, Fasulo D
	Siemens Corporate Research, Princeton, NJ, USA

PCN37	AN ECONOMIC EVALUATION OF CIRCULATING TUMOR CELLS DETECTION IN METASTATIC BREAST CANCER
	Rahman M¹, Malone D², Armstrong E²
	¹Ortho Clinical Diagnostics, Raritan, NJ, USA, ²University of Arizona, Tucson, AZ, USA

PCN38	COST-EFFECTIVENES ANALYSIS OF DOCETAXEL VERSUS STANDARD REGIMEN AS THE INDUCTION CHEMOTHERAPY OF LOCALLY ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA IN POLAND
	Walczak J¹, Lasota K¹, Malczak I¹, Pawlik D¹, Semeniuk A¹, Simon A¹, Bryl M¹, Lis J², Nogas G¹
	¹Arcana Institute, Cracow, Poland, ²Sanofi - Aventis sp. z o.o, Warsaw, Poland

PCN39	COST-EFFECTIVENESS ANALYSIS OF LUNG CANCER SCREENING WITH COMPUTED TOMOGRAPHY
	Chien CR¹, Chen THH²
	¹China Medical University Hospital, Taichung, Taiwan, ²National Taiwan University Hospital, Taipei, Taiwan

PCN40	A COST-EFFECTIVENESS ANALYSIS OF BENDAMUSTINE AT A TERTIARY CANCER CENTER
	Miller LA, Lau J, Lal LS, Dacosta Byfield S, Arbuckle R
	University of Texas M.D. Anderson Cancer Center, Houston, TX, USA

PCN41	EVIDENCE SYNTHESIS FOR MODELING THE NATURAL HISTORY OF ANAL PENILE AND OROPAHRYNGEAL CANCERS
	Abimbola T, Craig BM, Rollison D, Kumar A, Giuliano A
	Moffitt Cancer Center, Tampa, FL, USA

PCN42	BUDGETARY IMPACT OF METASTATIC RENAL CELL CARCINOMA (MRCC) TREATMENT ON THE COLOMBIAN GENERAL HEALTH SOCIAL SECURITY SYSTEM (SGSSS)
	Cardona AF¹, Caceres HA², Spath A², Lujan M³, Lopera D⁴, Otero JM⁵, Carranza H⁶, Godoy JI⁷
	¹Catalan Institute of Oncology - Hospital Germans Trias i Pujol, Barcelona, Spain, ²Pfizer S.A, Bogotá D.C, Colombia, ³Instituto de Cancerología - Clínica Las Américas - Universidad Pontificia Bolivariana, Medellín, NA, Colombia, ⁴Oncólogos de Occidente, Manizales, NA, Colombia, ⁵Foundation for Clinical and Molecular Cancer Research (FICMAC), Bogotá, NA, Colombia, ⁶Fundación Santa Fe de Bogotá, Bogotá, NA, Colombia, ⁷Hospital Militar Central, Bogotá DC, Colombia

PCN43	WITHDRAWN

PCN44	PHARMACOECONOMICAL ASPECT OF ONCOLOGICAL THERAPY
	Dubajova V¹, Foltán V¹, Tomek D², Dubaj M³
	¹Comenius University, Bratislava, Slovak Republic, ²Slovak Society for Pharmacoeconomics, Bratislava, Slovak Republic, ³University Hospital, Nitra, Slovak Republic

PCN45	PHARMACOECONOMIC EVALUATION OF THE USE OF SOMATOSTATIN ANALOGS HANDLING THE ASSOCIATED SYMPTOMS OF CARCINOID SYNDROME
	Salinas EG, Idrovo J, Zapata L
	Guia Mark, Mexico, DF, Mexico

PCN46	PHARMACOECONOMIC EVALUATION OF SUNITINIB MALATE FOR FIRST-LINE TREATMENT OF METASTATIC RENAL CELL CARCINOMA IN MEXICO
	Tenorio C¹, Vargas J², Rizo-Rios P³, Flores-Gil O⁴, Martínez-Fonseca J⁵, Mould-Quevedo J⁶, Davila-Loaiza G⁶
	¹Instituto Nacional de Cancerología, Mexico, DF, Mexico, ²Econopharma Consulting SA de CV, Mexico, DF, Mexico, ³Instituto Nacional de Cancerología, Mexico City, Mexico, ⁴ESCUELA MÉDICO NAVAL, Mexico City, Mexico, ⁵Econopharma Consulting SA de CV, Mexico City, Mexico, ⁶Pfizer Mexico, Mexico City, Mexico

PCN47	COST-EFFECTIVENESS OF DIFFERENT TREATMENTS IN PATIENTS WITH HEPATOCELLULAR CARCINOMA: A RETROSPECTIVE STUDY
	Chu PC¹, Chen CH¹, Wang JD², Hwang JS³
	¹National Taiwan University Hospital, Taipei, Taiwan, ²National Taiwan University, College of Public Health, Taipei, Taiwan, ³Academia Sinica, Taiwan, Taipei, Tuvalu

PCN48	THE COST-EFFECTIVENESS OF BORTEZOMIB FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA IN SWEDEN
	Rickert JB¹, Hornberger J², Dhawan R³, Liwing J⁴, Aschan J⁴, Lothgren M⁴
	¹Cedar Associates LLC, Menlo Park, CA, USA, ²Cedar Associates LLC and Stanford University, Menlo Park, CA, USA, ³Johnson & Johnson Pharmaceutical Services LLC, Raritan, NJ, USA, ⁴Janssen-Cilag AB, Sollentuna, Sweden

PCN49	COLORECTAL CANCER SCREENING FOR AVERAGE RISK INDIVIDUALS: AN ECONOMIC EVALUATION
	Au F¹, Heitman SJ¹, Manns BJ², Hilsden RJ¹
	¹University of Calgary, Calgary, AB, Canada, ²University of Calgary, Calgary, AB, AB, Canada

PCN50	COST-EFFECTIVENESS OF DOCETAXEL PLUS CYCLOPHOSPHAMIDE VERSUS DOXORUBICIN PLUS CYCLOPHOSPHAMIDE IN THE ADJUVANT TREATMENT OF OPERABLE BREAST CANCER
	Jones S¹, Chen L², Tangirala M³, Asmar L⁴, Airia P⁵, Thompson MF⁵
	¹US Oncology Research, Houston, TX, USA, ²sanofi-aventis U.S, Bridgewater NJ, NJ, USA, ³Smith Hanley Consulting Group LLC, Lake Mary, FL, USA, ⁴US Oncology, Houston, TX, USA, ⁵Cornerstone Research Group Inc, Burlington, ON, Canada

PCN51	PROJECTED LONG-TERM ECONOMIC OUTCOMES ASSOCIATED WITH BEVACIZUMAB TREATMENT IN PATIENTS WITH ADJUVANT TRIPLE-NEGATIVE BREAST CANCER TO INFORM EARLY DECISION MAKING
	Ray JA¹, Sabate E²
	¹F. Hoffmann-La Roche, Ltd, Basel, Switzerland, ²F. Hoffmann–La Roche Pharmaceuticals, AG, Basel, Switzerland

PCN52	ECONOMIC EVALUATION OF FULVESTRANT (FASLODEX®) AS AN ADDITIONAL ENDOCRINE STEP IN THE TREATMENT SEQUENCE FOR HORMONE-RECEPTOR POSITIVE ADVANCED AND METASTATIC BREAST CANCER IN ISRAEL
	Greenberg D¹, Rabinovich M², Hirsch M³
	¹Ben-Gurion University of the Negev, Beer-Sheva, Israel, ²AstraZeneca (Israel) Ltd, Raanana, Israel, ³AstraZeneca UK Ltd, Macclesfield, Cheshire, UK

PCN53	COST-EFFECTIVENESS OF HUMAN PAPILLOMAVIRUS VACCINE FOR PREVENTION OF CERVICAL CANCER IN TAIWAN
	Liu PH, Wang JD
	National Taiwan University, College of Public Health, Taipei, Taiwan

PCN54	COST-MINIMIZATION ANALYSIS OF FLUDARABINE ASSOCIATED TO ALEMTUZUMAB (FLUCAM) VERSUS THE ASSOCIATION OF FLUDARABINE, CYCLOPHOSPHAMIDE AND RITUXIMAB (FCR) IN THE SECOND LINE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) UNDER THE BRAZILIAN PRIVATE HEALTH CARE SYSTEM PERSPECTIVE
	Teich N¹, Teich V¹, Benitez R¹, Schiola A²
	¹MedInsight, Rio de Janeiro, Brazil, ²Bayer Schering Pharma Brazil, São Paulo, Brazil

PCN55	ASSESSING THE MAJOR DRIVERS FOR THE INCREASED HEALTH CARE COSTS ASSOCIATED WITH BREAST CANCER
	Rahman M¹, Weinstein R², Wilcox M², Matcho A², Price S³
	¹Ortho Clinical Diagnostics, Raritan, NJ, USA, ²PRD USA, Titusville, NJ, USA, ³Centocor Ortho Biotech Services, LLC, Horsham, PA, USA

PCN56	IMPACT OF BONE METASTASES (BM) ON HEALTH CARE COSTS BEFORE AND AFTER OCCURRENCE OF SKELETAL RELATED EVENTS (SRES) IN MEN WITH PROSTATE CANCER (PC)
	Oglesby A¹, Delea T², Hagiwara M², Zilber S², Berger A²
	¹Amgen, Inc., Thousand Oaks, CA, USA, ²Policy Analysis Inc. (PAI), Brookline, MA, USA

PCN57	ASSESSING THE MAJOR DRIVERS FOR THE INCREASED HEALTH CARE COSTS ASSOCIATED WITH PROSTATE CANCER
	Rahman M¹, Weinstein R², Wilcox M², Matcho A², Raghavan B¹
	¹Ortho Clinical Diagnostics, Raritan, NJ, USA, ²PRD USA, Titusville, NJ, USA

PCN58	HEALTH CARE COSTS IN WOMEN WITH INCIDENT METASTATIC BREAST CANCER RECEIVING CHEMOTHERAPY AS THEIR PRINCIPAL TREATMENT MODALITY
	Vera-Llonch M¹, Glass A², Weycker D¹, Borker R³, Gao S³, Oster G¹
	¹PAI, Brookline, MA, USA, ²Kaiser Permanente, Northwest Region, Portland, OR, USA, ³Amgen, Thousand Oaks, CA, USA

PCN59	INCIDENCE RATE AND BURDEN OF ILLNESS OF CERVICAL CANCER IN THE UNITED STATES
	Srivastava K¹, Rai MK², Siddiqui MK¹, Goyal R², Chawla A¹, Takyar S³, Sharma S¹
	¹Heron Health Private Limited, Chandigarh, India, ²Heron Health Private Limited, Plot No 22-23, Rajiv Gandhi IT Park, Chandigarh, India, ³Heron Health Private Limited, Plot No. 22-23, Rajiv Gandhi IT Park, Chandigarh, India

PCN60	COSTS OF CARE FOR ELDERLY METASTATIC PROSTATE CANCER PATIENTS OVER TIME
	Obeidat NA¹, Onukwugha E², Bikov K¹, Seal B³, Mullins CD²
	¹University of Maryland, Baltimore, MD, USA, ²University of Maryland School of Pharmacy, Baltimore, MD, USA, ³Sanofi-Aventis, Bridgewater, NJ, USA

PCN61	THE ECONOMIC BURDEN OF METASTATIC BREAST CANCER
	Foster T¹, Miller JD¹, Boye ME², Blieden MB¹, Ancukiewicz V¹, Russell MW¹
	¹Abt Bio-Pharma Solutions, Inc., Lexington, MA, USA, ²Eli Lilly and Company, Indianapolis, IN, USA

PCN62	FIRST YEAR COST EXPENDITURES ASSOCIATED WITH HEAD AND NECK CANCER DIAGNOSIS IN THE U.S. MANAGED CARE POPULATION
	Choi JC¹, Joish VN², Camacho F³, Mullins CD⁴
	¹Rutgers University, Piscataway, NJ, USA, ²Sanofi-Aventis, Bridgewater, NJ, USA, ³Penn State College of Medicine, Hershey, PA, USA, ⁴University of Maryland School of Pharmacy, Baltimore, MD, USA

PCN63	DIFFERENT TREATMENT PATTERNS COSTS IN METASTATIC BREAST CANCER (MBC) EXPOSED TO ANTHRACYCLINHES AND TAXANES (AT) IN 3 DIFFERENT MEXICAN PUBLIC HOSPITALS
	Juarez-Garcia A¹, Hernandez-Rivera G², Gómez-Roel X², Uc-Coyoc R¹, Rangel S¹, Vargas-Valencia JJ³, Martínez-Fonseca J³, Donato BM⁴, Litalien G⁴
	¹Bristol-Myers Squibb, México City, Mexico, ²Bristol-Myers Squibb, Mexico City, Mexico, ³Econopharma Consulting SA de CV, Mexico City, Mexico, ⁴Bristol-Myers Squibb, Wallingford, CT, USA

PCN64	THE ECONOMIC BURDEN ASSOCIATED WITH METASTATIC COLORECTAL CANCER
	Long SR¹, Foley KA², Wang PF³, Barber B³, Zhao Z³
	¹Thomson Reuters, Hampden, ME, USA, ²Thomas Jefferson University, Philadelphia, PA, USA, ³Amgen, Inc., Thousand Oaks, CA, USA

PCN65	COST OF FIRST LINE METASTATIC COLON CANCER CHEMOTHERAPIES IN HUNGARY
	Jozsa G
	University of West Hungary, Sopron, Hungary

PCN66	COST OF ANTHRACYCLINE-INDUCED CARDIOTOXICITY AMONG U.S. BREAST CANCER PATIENTS
	Choi JC¹, Chang JD², Seal B³, Tangirala M⁴, Mullins CD⁵
	¹Rutgers University, Piscataway, NJ, USA, ²Beth Israel Deaconess Medical Center, Boston, MA, USA, ³Sanofi-Aventis, Bridgewater, NJ, USA, ⁴Smith Hanley Consulting Group LLC, Lake Mary, FL, USA, ⁵University of Maryland School of Pharmacy, Baltimore, MD, USA

PCN67	THE COST OF WAITING: ECONOMIC BENEFIT OF REDUCING WAITING TIMES FOR EARLY BREAST CANCER RADIOTHERAPY
	Cromwell IA, Johnson A, Mackillop W
	Queen's University, Kingston, ON, Canada

PCN68	COST-EFFECTIVENESS OF CETUXIMAB (ERBITUX^TM) FOR THE FIRST LINE TREATMENT OF SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN) IN CANADA
	Sambrook JC¹, Levy AR¹, Johnston KM², Ricard NJ³, Bourgault C³, Donato BM⁴, Hotte SJ⁵, Chasen MR⁶, Briggs A⁷
	¹Oxford Outcomes Ltd, Vancouver, BC, Canada, ²University of British Columbia, Vancouver, BC, Canada, ³Bristol-Myers Squibb Canada, St-Laurent, QC, Canada, ⁴Bristol-Myers Squibb, Wallingford, CT, USA, ⁵McMaster University, Hamilton, ON, Canada, ⁶McGill University, Montreal, QC, Canada, ⁷University of Glasgow, Glasgow, UK

PCN69	COST-EFFECTIVENESS OF FIRST-LINE COMBINATION TREATMENT WITH BEVACIZUMAB PLUS FOLFIRI VERSUS FOLFIRI IN PATIENTS WITH METASTATIC COLORECTAL CANCER: A UK PERSPECTIVE
	Gyldmark M¹, Aultman R¹, Siebert U², Sabate E³
	¹F. Hoffmann-La Roche, Ltd, Basel, Switzerland, ²UMIT – University for Health Sciences, Medical Informatics and Technology, Hall i.T, Austria, ³F. Hoffmann–La Roche Pharmaceuticals, AG, Basel, Switzerland

PCN70	MODELLING THE COST EFFECTIVENESS OF FIRST-LINE COMBINATION TREATMENT WITH BEVACIZUMAB PLUS IRINOTECAN AND INFUSIONAL FLUOROPYRIMIDINES VERSUS IRINOTECAN AND INFUSIONAL FLUOROPYRIMIDINES IN METASTATIC COLORECTAL CANCER PATIENTS IN SWEDEN
	Holmberg C¹, Aultman R², Siebert U³, Sabate E⁴, Gyldmark M²
	¹F. Hoffmann-La Roche, AB, Stockholm, Sweden, ²F. Hoffmann-La Roche, Ltd, Basel, Switzerland, ³UMIT – University for Health Sciences, Medical Informatics and Technology, Hall i.T, Austria, ⁴F. Hoffmann–La Roche Pharmaceuticals, AG, Basel, Switzerland

PCN71	COST-EFFECTIVENESS (CE) ANALYSIS OF ERBB2-TARGETED THERAPIES IN WOMEN WITH TRASTUZUMAB (TZ)-REFRACTORY ERBB2+ METASTATIC BREAST CANCER (MBC) AND LIMITED EXPOSURE TO PRIOR CHEMOTHERAPY (CT)
	Delea T¹, Sofrygin O¹, Tappenden P², Browning D³, Amonkar MM⁴, Karnon J², Lykopoulos K⁵
	¹Policy Analysis Inc. (PAI), Brookline, MA, USA, ²University of Sheffield, Sheffield, UK, ³GlaxoSmithKline, London, UK, ⁴GlaxoSmithKline, Collegeville, PA, USA, ⁵GlaxoSmithKline, Uxbridge, UK

PCN72	COST-UTILITY ANALYSIS OF GEFITINIB VERSUS DOCETAXEL IN A MEXICAN PUBLIC INSTITUTION
	Anaya P, López RJ, Polanco AC
	AstraZeneca, Naucalpan, Edo. de Méx, Mexico

PCN73	USING SHORT-TERM RESPONSE TO PREDICT LONG-TERM OUTCOMES IN PATIENTS WITH IMATINIB-RESISTENT OR IMATINIB-INTOLERANT CHRONIC MYELOID LEUKAEMIA
	Taylor M¹, Saxby R¹, Davis C²
	¹University of York, York, UK, ²Bristol-Myers Squibb, Wallingford, CT, USA

PCN74	COST UTILITY OF POSACONAZOLE VERSUS FLUCONAZOLE/ITRACONAZOLE THERAPY IN THE PROPHYLAXIS AGAINST INVASIVE FUNGAL INFECTIONS AMONG HIGH-RISK NEUTROPENIC PATIENTS IN MEXICO
	Rely K¹, Pierre KA², Salinas EG³
	¹Network on the Economic Evaluation of Healthcare Programmes and its Applications to Decision Making in Latin American Countries, Mexico, DF, Mexico, ²Johns Hopkins University, Bloomberg School of Public Health, Baltimore , MD, MD, USA, ³Hospital Infantil de México Federico Gómez, Mexico, DF, Mexico

PCN75	THE IMPACT OF NEUTROPENIC COMPLICATIONS ON SHORT-TERM DISABILITY IN PATIENTS WITH CANCER RECEIVING CHEMOTHERAPY
	Song X¹, Fowler R², McGuffie K², Hurley D³, Barron RL³
	¹Thomson Reuters, Cambridge, MA, USA, ²Thomson Reuters, Washington, DC, USA, ³Amgen, Inc., Thousand Oaks, CA, USA

PCN76	REVISITING CHERNOBYL: THE LONG-RUN IMPACT OF THE NUCLEAR ACCIDENT ON LABOR MARKET OUTCOMES
	Zelenska T
	Georgia State University, Atlanta, GA, USA

PCN77	HEALTH CARE RESOURCE UTILIZATION ASSOCIATED WITH ESCALATING IMATINIB VERSUS SWITCHING TO DASATINIB IN PATIENTS WITH CHRONIC MYELEGENOUS LEUKEMIA
	Yu AP¹, Guo A², Guérin A¹, Latremouille-Viau D¹, Tsaneva M¹, Xie J¹, Signorovitch J¹, Williams D², Wu E¹
	¹Analysis Group, Inc., Boston, MA, USA, ²Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA

CANCER Patient-Reported Outcomes Studies
PCN78	PREFERENCES IN MULTIPLE MYELOMA TREATMENT – WHAT DO PHYSICIANS THINK?
	Mühlbacher AC¹, Berndt K², Schreder CH², Nübling M³
	¹HS Neubrandenburg, Neubrandenburg, Germany, ²Janssen-Cilag GmbH, Neuss, Germany, ³Gesellschaft für empirische Beratung mbH, D- 79211 Denzlingen, Germany

PCN79	HEALTH RELATED QUALITY OF LIFE IN THE DIFFERENT STAGES OF NON-HODGKIN LYMPHOMA IN PATIENTS ATTENDED IN THE SOCIAL SECURITY MEXICAN INSTITUTE
	Balderas-Peña LMA¹, Contreras-Hernandez I², Mould-Quevedo J³, Garduño-Espinosa J², Morgan-Villela G⁴
	¹Social Security Mexican Institute, pecialties' Hospital. Western National Medical Center, Guadalajara, Mexico, ²Social Security Mexican Institute, Mexico City, Mexico, ³Pfizer Mexico, Mexico City, Mexico, ⁴Social Security Mexican Institute, Guadalajara, Mexico

PCN80	HEALTH RELATED QUALITY OF LIFE IN THE DIFFERENT STAGES OF BREAST CANCER IN PATIENTS ATTENDED IN THE SOCIAL SECURITY MEXICAN INSTITUTE
	Balderas-Peña LMA¹, Contreras-Hernandez I², Mould-Quevedo J³, Sat-Muñoz D⁴, Garduño-Espinosa J², Morgan-Villela G⁴
	¹Social Security Mexican Institute, pecialties' Hospital. Western National Medical Center, Guadalajara, Mexico, ²Social Security Mexican Institute, Mexico City, Mexico, ³Pfizer Mexico, Mexico City, Mexico, ⁴Social Security Mexican Institute, Guadalajara, Mexico

PCN81	HEALTH RELATED QUALITY OF LIFE IN THE DIFFERENT STAGES OF COLORECTAL CANCER IN PATIENTS ATTENDED IN THE SOCIAL SECURITY MEXICAN INSTITUTE
	Contreras-Hernandez I¹, Balderas-Peña LMA², Mould-Quevedo J³, Garduño-Espinosa J¹, Morgan-Villela G⁴
	¹Social Security Mexican Institute, Mexico City, Mexico, ²Social Security Mexican Institute, pecialties' Hospital. Western National Medical Center, Guadalajara, Mexico, ³Pfizer Mexico, Mexico City, Mexico, ⁴Social Security Mexican Institute, Guadalajara, Mexico

PCN82	HFS 14: A SPECIFIC QUALITY OF LIFE INSTRUMENT FOR PATIENTS WITH HAND-FOOT SYNDROME
	Taieb C¹, Sibaud V²
	¹Pierre Fabre, Boulogne, France, ²AVENE, LAVAUR, France

PCN83	A MULTINATIONAL STUDY OF PATIENT PREFERENCE VALUES FOR HEALTH STATES FOR CHRONIC MYELOGENOUS LEUKEMIA
	Szabo SM¹, Davis C², Cortes J³, Levy AR¹
	¹Oxford Outcomes Ltd, Vancouver, BC, Canada, ²Bristol-Myers Squibb, Wallingford, CT, USA, ³MD Anderson Cancer Center, Houston, TX, USA

PCN84	VALIDATION OF THE EUROQOL EQ-5D IN PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA (RR MCL)
	Cuyun Carter G¹, Liepa AM¹, Zimmermann AH¹, Morschhauser F²
	¹Eli Lilly and Company, Indianapolis, IN, USA, ²Centre Hospitalier Universitaire, Lille, France

PCN85	TESTING THE MEASUREMENT EQUIVALENCE OF PAPER AND INTERACTIVE VOICE RESPONSE (IVR) VERSIONS OF THE EORTC QLQ-C30
	Lundy JJ¹, Coons SJ¹, Aaronson NK²
	¹University of Arizona, Tucson, AZ, USA, ²The Netherlands Cancer Institute, Amsterdam, Netherlands

PCN86	TEST-RETEST RELIABILITY OF AN INTERACTIVE VOICE RESPONSE (IVR) VERSION OF THE EQ-5D IN A SAMPLE OF CANCER SURVIVORS
	Lundy JJ, Coons SJ
	University of Arizona, Tucson, AZ, USA

PCN87	TEST-RETEST RELIABILITY OF AN INTERACTIVE VOICE RESPONSE (IVR) VERSION OF THE EORTC QLQ-C30
	Lundy JJ¹, Coons SJ¹, Aaronson NK²
	¹University of Arizona, Tucson, AZ, USA, ²The Netherlands Cancer Institute, Amsterdam, Netherlands

PCN88	LEVERAGING PATIENT-REPORTED OUTCOMES TO DEFINE FATIGUE IN CANCER
	Scott J¹, Piault E², Lasch KE², Jernigan KA²
	¹Mapi Values, Macclesfield, Cheshire, UK, ²Mapi Values, LLC, Boston, MA, USA

PCN89	FACTORS IMPACTING THE HEALTH RELATED QUALITY OF LIFE IN FEMALE BREAST CANCER PATIENTS – AN OBSERVATIONAL, CROSS-SECTIONAL STUDY
	Cristino J, Piercy J, Worsfold A
	Adelphi Group, Bollington, Cheshire, UK

PCN90	A METHODOLOGICAL INVESTIGATION TO DEFINE A CLINICALLY RELEVANT CUT-OFF POINT IN THE ORDINAL SCALE OF THE EORTC QLQ-C30 QUESTIONNAIRE
	Quinten C¹, Martinelli F¹, Coens C¹, Maringwa J¹, Cleeland C², Fechtner H³, Gotay C⁴, Greimel E⁵, King M⁶, Osoba D⁷, Taphoorn MJB⁸, Reeve B⁹, Ringash J¹⁰, Schmucker-Von Koch J¹¹, Weis J¹², Bottomley A¹
	¹EORTC, Brussels, Belgium, ²U.T.M.D. Anderson Cancer Center, Houston, TX, USA, ³City Hospital Magdeburg, Magdeburg, Germany, ⁴University of British Columbia, Vancouver, BC, Canada, ⁵Medical University Graz, Graz, Austria, ⁶University of Sydney, Sydney, Australia, ⁷QOL Consulting, West Vancouver, BC, Canada, ⁸VU University Medical Center/Medical Center Haaglanden, Den Haag, Netherlands, ⁹National Cancer Institute, Bethesda, MD, USA, ¹⁰The Princess Margaret Hospital, Toronto, ON, Canada, ¹¹University of Regensburg, Regensburg, Germany, ¹²University of Freiburg, Freiburg, Germany

PCN91	PROVISION OF QUALITY OF LIFE INFORMATION AND PHYSICIAN TRUST AMONG FAMILIES OF CHILDREN WITH LIFE-LIMITED CONDITIONS
	Huang IC, Knapp C, Shenkman E
	University of Florida, Gainesville, FL, USA

PCN92	HOW DOES TRUST IN PHYSICIANS AFFECT PARENTS' TREATMENT DECISION MAKING FOR THEIR CHILDREN WITH LIFE-LIMITING CONDITIONS?
	Huang IC, Knapp C, Shenkman E
	University of Florida, Gainesville, FL, USA

PCN93	ONCOLOGIC PATIENT SATISFACTION IN ONCOLOGIC SERVICES IN A TERTIARY REFERRAL CENTER AT THE SOCIAL SECURITY MEXICAN INSTITUTE
	Contreras-Hernandez I¹, Balderas-Peña LMA², Mould-Quevedo J³, Ruiz-Duran MDR⁴, Hernández-Carbajal I⁵, Garduño-Espinosa J¹, Morgan-Villela G⁶
	¹Social Security Mexican Institute, Mexico City, Mexico, ²Social Security Mexican Institute, pecialties' Hospital. Western National Medical Center, Guadalajara, Mexico, ³Pfizer Mexico, Mexico City, Mexico, ⁴Universidad de Guadalajara, Guadalajara, Mexico, ⁵Social Security Mexican Institute, Mexico, Mexico, ⁶Social Security Mexican Institute, Guadalajara, Mexico
CANCER Health Care Use & Policy Studies
PCN94	LEVEL OF BREAST CANCER EARLY DETECTION AWARENESS OF BRAZILIAN WOMEN
	Caleffi M¹, Boscatti FHG², Muranaka AH³
	¹FEMAMA ( National Coalition of non-profit organizations to support Breast Cancer Care), Porto Alegre, RS, Brazil, ²Universidade de São Paulo, Sao Paulo, SP, Brazil, ³Universidade Federal de São Paulo, Sao Paulo, SP, Brazil

PCN95	STRUGGLING WITH EXPENSIVE NEW CANCER THERAPIES: A NATIONAL SURVEY OF ONCOLOGISTS IN THE UNITED STATES
	Neumann PJ¹, Palmer JA¹, Fang C¹, Nadler E², Ubel PA³
	¹Tufts-New England Medical Center, Boston, MA, USA, ²Baylor University Medical Center, Dallas, TX, USA, ³University of Michigan, Ann Arbor, MI, USA

PCN96	ESTIMATING THE TIME OF PRODUCTIVITY LOST OF PATIENTS WITH CANCER AND MUSCULAR-SKELETAL DISEASES IN SLOVAKIA
	Petrova L¹, Foltan V¹, Binder R¹, Bielik J²
	¹Comenius University, Bratislava, Slovak Republic, ²Trencin University, Trencin, Slovak Republic

PCN97	PHYSICIAN REFERRAL PATTERNS AMONG ELDERLY PATIENTS WITH STAGE IV PROSTATE CANCER (PCA): AN ANALYSIS USING SEER-MEDICARE DATA
	Onukwugha E¹, Mullins CD¹, Seal B², Hussain A³
	¹University of Maryland School of Pharmacy, Baltimore, MD, USA, ²Sanofi-Aventis, Bridgewater, NJ, USA, ³University of Maryland School of Medicine, Baltimore, MD, USA

PCN98	IMPACT OF RECENT ERYTHROPOIESIS-STIMULATING AGENT (ESA) POLICY CHANGES ON DOSING PATTERNS IN CANCER CHEMOTHERAPY PATIENTS
	Lefebvre P¹, Lafeuille MH¹, Bailey R², Vekeman F³, Piech CT², McKenzie RS²
	¹Groupe d'analyse, Ltee, Montreal, QC, Canada, ²Centocor Ortho Biotech Services, LLC, Horsham, PA, USA, ³Groupe d'analyse, Ltee, Montréal, QC, Canada

PCN99	PROSTATE CANCER-RELATED VISITS AMONG PATIENTS TREATED WITH GNRH AGONIST DEPOTS: DO LONGER DURATION DEPOTS REDUCE NUMBER OF VISITS?
	Ogbonnaya A¹, Nielsen SK², Stern L¹, Wiederkehr D¹
	¹Analytica International, New York, NY, USA, ²Ferring International Center, Saint-Prex, Switzerland

PCN100	EVALUATING THE EFFECTIVENESS OF PRIMARY PROPHYLACTIC G-CSF UTILIZED AS AN ADJUNCT TO CHEMOTHERAPY IN BREAST CANCER PATIENTS
	Chen CH¹, Chan ALF²
	¹Chi-Mei Medical Center, Tainan, AL, Taiwan, ²Department of Pharmacy, Chi Mei Medical Center, Tainan, Taiwan

PCN101	BREAST CANCER SCREENING OR DIAGNOSTIC PROCEDURES IN POSTMENOPAUSAL WOMEN INITIATING OSTEOPOROSIS MEDICATIONS
	Foster SA¹, Whangbo A², Mitchell BD¹, Viswanathan S³, Muram D¹, Mershon JL¹, Khare A², Kar R², Yurgin NR¹, Vedarajan G²
	¹Eli Lilly and Company, Indianapolis, IN, USA, ²ZS Associates, New York, NY, USA, ³ZS Associates, Boston, MA, USA

PCN102	IMPACT OF RADIOTHERAPY SEQUENCE WITH SURGERY ON SURVIVAL FOR PATIENTS WITH RESECTABLE COLORECTAL CANCER
	Gaitonde U, Syeda S, Wu WK
	St. John's University, Queens, NY, USA

PCN103	SCREENING MAMMOGRAPHY TRENDS AMONG WOMEN IN A FEE-FOR-SERVICE MEDICAID POPULATION
	Bhanegaonkar AJ, Khanna R, Madhavan SS
	West Virginia University, Morgantown, WV, USA

PCN104	HEALTH WORKERS' WORK ENVIRONMENT SATISFACTION IN ONCOLOGIC SERVICES AT THE SOCIAL SECURITY MEXICAN INSTITUTE
	Contreras-Hernandez I¹, Balderas-Peña LMA², Mould-Quevedo J³, Ruiz-Duran MDR⁴, Garduño-Espinosa J¹, Davila-Loaiza G³, Morgan-Villela G⁵
	¹Social Security Mexican Institute, Mexico City, Mexico, ²Social Security Mexican Institute, pecialties' Hospital. Western National Medical Center, Guadalajara, Mexico, ³Pfizer Mexico, Mexico City, Mexico, ⁴Universidad de Guadalajara, Guadalajara, Mexico, ⁵Social Security Mexican Institute, Guadalajara, Mexico

PCN105	GUIDELINES AND CANCER SCREENING IN THE UNITED STATES AND CANADIAN HEALTH SYSTEMS
	Kadiyala S¹, Strumpf EC²
	¹University of Washington, Seattle, WA, USA, ²McGill University, Monreal, QC, Canada

PCN106	THE IMPACT OF CANCER SCREENING GUIDELINE INFORMATION ON CANCER DETECTION
	Kadiyala S¹, Strumpf EC²
	¹University of Washington, Seattle, WA, USA, ²McGill University, Monreal, QC, Canada

PCN107	WITHDRAWN

PCN108	IMPACT OF NEW DRUGS AND BIOLOGICALS ON TREATMENT AND COSTS FOR COLORECTAL CANCER
	Shah ND¹, Van Houten H¹, Vermeulen L²
	¹Mayo Clinic, Rochester, MN, USA, ²University of Wisconsin Hospital and Clinics, Madison, WI, USA

PCN109	BREAST CANCER PREVALENCE AND HEALTH CARE UTILIZATION AND COST TRENDS AMONG FEE-FOR-SERVICE FEMALE RECIPIENTS IN A STATE MEDICAID PROGRAM
	Khanna R, Madhavan SS, Bhanegaonkar AJ
	West Virginia University, Morgantown, WV, USA

PCN110	A RETROSPECTIVE CLAIMS DATABASE COMPARISON OF SORAFENIB AND SUNITINIB DOSING PATTERNS IN PATIENTS WITH RENAL CELL CARCINOMA (RCC)
	Keefe S¹, Moyneur E², Barghout V³, Flaherty KT¹
	¹University of Pennsylvania, Philadelphia, PA, USA, ²StatLog Consulting Inc, L'Ange-Gardien, QC, Canada, ³Bayer HealthCare Pharmaceuticals, Inc., Wayne, NJ, USA

PCN111	INFLUENCE OF AGE ON COMORBIDITIES AND TREATMENT IN PATIENTS WITH RENAL CELL CARCINOMA (RCC): A RETROSPECTIVE CLAIMS DATABASE ANALYSIS
	Dorff TB¹, Moyneur E², Barghout V³, Quinn DI¹
	¹Keck School of Medicine, Los Angeles, CA, USA, ²StatLog Consulting Inc, L'Ange-Gardien, QC, Canada, ³Bayer HealthCare Pharmaceuticals, Inc., Wayne, NJ, USA

PCN112	OFF-LABEL USE OF ONCOLOGY DRUGS IN A COMMUNITY ONCOLOGY EMR DATABASE
	Stephen R¹, Knopf K², Reynolds MW¹, Luo W¹, Fraeman K³
	¹United BioSource Corporation, Lexington, MA, USA, ²Pacific Hematology/Oncology Associates, San Francsico, CA, USA, ³United BioSource Corporation, Bethesda, MD, USA

POSTER PRESENTATIONS SESSION I
SET-UP:	Monday May 18, 2009 - 7:30AM-8:00AM
POSTER DISPLAY HOURS:	Monday May 18, 2009 - 8:00AM-8:00PM
POSTER AUTHOR DISCUSSION HOUR:	Monday May 18, 2009 - 6:00PM-7:00PM
DISMANTLE:	Monday May 18, 2009 - 8:00PM-8:30PM

GASTROINTESTINAL DISORDERS Clinical Outcomes Studies
PGI1	A SYSTEMATIC REVIEW ON KUSHENIN VERSUS WESTERN MEDICINES FOR PATIENTS WITH CHRONIC HEPATITIS B
	Bian B¹, Shao R², Xia Y², Guo JJ³, Chen Y²
	¹University of Cincinnati, Cincinnanti, OH, USA, ²China Pharmaceutical University, Nanjing, Jiangsu, China, ³University of Cincinnati, Cincinnati, OH, USA

PGI2	CHANGES IN PRESCRIPTIONS DISPENSED ON PROTON PUMP INHIBITORS (PPIS) FOLLOWING NEW RESTRICTIONS FOR REIMBURSEMENT – A NATIONWIDE NORWEGIAN PRESCRIPTION DATABASE STUDY
	Jonasson C¹, Tvete I², Jørgensen E¹, Hatlebakk JG³
	¹AstraZeneca AS, Oslo, Norway, ²Norwegian Computing Centre, Oslo, Norway, ³University of Bergen, Bergen, Norway

PGI3	RISK OF UPPER GASTROINTESTINAL ADVERSE EVENTS AND THE EFFECT OF ACID-SUPPRESSIVE THERAPY IN PATIENTS RECEIVING ACETYLSALICYLIC ACID FOR CARDIOVASCULAR RISK MANAGEMENT
	Johansson S¹, Farahmand B², Joelson S¹, Estborn L¹, Wallander MA³
	¹AstraZeneca R&D, Mölndal, Sweden, ²AstraZeneca R&D, Södertälje, Sweden, ³Uppsala University, Uppsala, Sweden

GASTROINTESTINAL DISORDERS Cost Studies
PGI4	NUMBER-NEEDED-TO-TREAT (NNT) ANALYSIS: REMISSION RATES FOR ADALIMUMAB VS. INFLIXIMAB IN CROHN'S DISEASE
	Johnson S¹, Kaltenboeck A¹, Horn C¹, Wu E¹, Majethia S², Mulani P², Chao J²
	¹Analysis Group, Inc., Boston, MA, USA, ²Abbott Laboratories, Abbott Park, IL, USA

PGI5	PUBLISHED COST-EFFECTIVENESS RESULTS FOR CHRONIC HEPATITIS B AND C – A COMPARATIVE ANALYSIS
	Ho J, Todorova L
	Dymaxium Inc, Toronto, ON, Canada

PGI6	COST EFFECTIVENESS ANALYSIS OF ANTI-TNF-ALPHA; DRUGS FOR REFRACTORY ULCERATIVE COLITIS
	Xie F, Blackhouse G, Assasi N, Hopkins R, Gaebel K, O'Reilly D, Tarride JE, Goeree RA
	McMaster University, Hamilton, ON, Canada

PGI7	COST-EFFECTIVENESS ANALYSIS OF ADALIMUMAB VS. CERTOLIZUMAB MAINTENANCE THERAPIES FOR MODERATE TO SEVERE CROHN'S DISEASE
	Johnson S¹, Kaltenboeck A¹, Horn C¹, Mulani P², Majethia S², Chao J²
	¹Analysis Group, Inc., Boston, MA, USA, ²Abbott Laboratories, Abbott Park, IL, USA

PGI8	COST-EFFECTIVENESS OF PEG-IFN ALPHA 2A OR 2B PLUS RIBAVIRIN IN THE TREATMENT OF CHRONIC HEPATITIS C IN MEXICO
	Salinas Escudero G¹, Idrovo J², Rivas R², Ramirez Rodriguez J³, Rico Alba IA⁴, Zapata L²
	¹Hospital Infantil de México Federico Gómez, México DF, Distrito Federal, Mexico, ²Guia Mark, Mexico, DF, Mexico, ³CMNO, Guadalajara, Jalisco, Mexico, ⁴Guia Mark, México, DF, Mexico

PGI9	ECONOMIC ANALYSIS OF THE POTENTIAL USAGES OF ALVIMOPAN AND METHYLNALTREXONE AT A TERTIARY CANCER CENTER
	Lal LS¹, Xu R², Smith WD¹, Miller LA³, Arbuckle R¹
	¹University of Texas MD Anderson Cancer Center, Houston, TX, USA, ²University of Houston, Houston, TX, USA, ³University of Texas M.D. Anderson Cancer Center, Houston, TX, USA

PGI10	BURDEN OF SURGICALLY RESECTED GASTROINTESTINAL STROMAL TUMORS (GIST) IN THE US
	Rubin JL¹, Sanon M¹, Taylor DC¹, Coombs J², Thompson D¹
	¹i3 Innovus, Medford, MA, USA, ²Novartis Pharmaceuticals Corporation, Florham Park, NJ, USA

PGI11	ECONOMIC EVALUATION OF INFLIXIMAB AND ADALIMUMAB FOR CROHN'S DISEASE
	Hughes DA¹, Kikuchi T¹, Bodger K²
	¹Bangor University, Bangor, UK, ²University of Liverpool, Liverpool, UK

GASTROINTESTINAL DISORDERS Patient-Reported Outcomes Studies
PGI12	THE EFFECT OF A PRIOR AUTHORIZATION PROGRAM FOR PROTON-PUMP INHIBITORS ON MEDICATION PERSISTENCE AMONG THE ELDERLY
	Devine JW¹, Trice S¹, Allerman AA¹, Bacon TA²
	¹Department of Defense Pharmacoeconomic Center, Fort Sam Houston, TX, USA, ²TRICARE Management Activity, Falls Church, VA, USA

PGI13	RESPONSIVENESS TO CHANGE AND CLINICALLY RELEVANT IMPROVEMENTS OF THE SF-36 QUESTIONNAIRE IN SWEDISH PATIENTS WITH GASTROESOPHAGEAL REFLUX DISEASE
	Wahlqvist P, Medin J, Rydén A
	AstraZeneca R&D Mölndal, Mölndal, Sweden

PGI14	RESPONSIVENESS TO CHANGE AND CONSTRUCT VALIDITY OF THE WORK PRODUCTIVITY AND ACTIVITY IMPAIRMENT QUESTIONNAIRE FOR GASTROESOPHAGEAL REFLUX DISEASE (WPAI:GERD) IN SWEDISH PATIENTS
	Wahlqvist P¹, Medin J¹, Karlsson M¹, Reilly MC²
	¹AstraZeneca R&D Mölndal, Mölndal, Sweden, ²Margaret Reilly Associates, Inc, New York, NY, USA

PGI15	ADULT CANADIANS SUFFERING FROM ACID RELATED DISEASES: PATIENT REPORTED ATTITUDES, PERCEPTIONS, AND IMPACT ON THEIR LIFE
	Beamer B, Ciobanu A, Liovas A
	AstraZeneca, Mississauga, ON, Canada

GASTROINTESTINAL DISORDERS Health Care Use & Policy Studies
PGI16	FACTORS INFLUENCING GASTROESOPHAGEAL REFLUX DISEASE OUTPATIENTS' CHOICES TO ACCESS DIFFERENT TIERS OF MEDICAL FACILITIES: THE PRELIMINARY STUDY OF A DISCRETE CHOICE EXPERIMENT
	Tseng JH¹, Chen LC¹, Kuo C², Lu C¹
	¹Kaohsiung Medical University Hospital, Kaohsiung, Taiwan, ²Kaohsiung Municipal Hsiao-Kang Hospital, Kaohsiung, Taiwan

PGI17	EXAMINATION OF PROTON PUMP INHIBITOR (PPI) UTILIZATION AMONG GASTROESOPHAGEAL REFLUX (GERD) PATIENTS USING ELECTRONIC MEDICAL RECORDS (EMR)
	Mody R¹, Meissner BL², Shaheen N³
	¹Takeda Pharmaceuticals North America, Inc, Deerfield, IL, USA, ²Xcenda, Palm Harbor, FL, USA, ³University of North Carolina, Chapel Hill, NC, USA

PGI18	EXAMINING PROTON PUMP INHIBITOR (PPI) TREATMENT PATTERNS AMONG PATIENTS WITH SELECTED UPPER GASTROINTESTINAL CONDITIONS
	De Leon MC¹, Mody R¹, Boulanger L²
	¹Takeda Pharmaceuticals, Deerfield, IL, USA, ²Abt Bio-Pharma Solutions, Inc., Lexington, MA, USA

PGI19	REDUCING MEDICAL COSTS THROUGH PREVENTING LABORATORY ERRORS: AN EVALUATION OF BAYESIAN NETWORK MODEL IN DETECTING ERRORS OF LIVER ENZYME LAB VALUES
	Le QA, Doctor JN
	University of Southern California, Los Angeles, CA, USA

PGI20	CLINICAL OUTCOMES AND PATTERNS OF CARE IN PATIENTS WITH CHRONIC LIVER DISEASE, BRIDGING FIBROSIS, AND CIRRHOSIS: ADAPTABLE METHODOLOGIES FOR THE DESIGN, IMPLEMENTATION AND CONDUCT OF MULTI-NATIONAL, RETROSPECTIVE CHART REVIEW STUDIES
	Payne KA¹, Lordan N², Duran B², Ishak KJ¹, Grotzinger K³
	¹United BioSource Corporation, Montreal, QC, Canada, ²United BioSource Corporation, Lexington, MA, USA, ³GlaxoSmithKline, Collegeville, PA, USA

PGI21	ASSESSMENT OF THE EFFECTIVENESS OF “AFFINEX FLAT STOMACH “ AFTER 14 DAYS OF TREATMENT
	Taieb C
	Pierre Fabre, Boulogne, France

POSTER PRESENTATIONS SESSION I
SET-UP:	Monday May 18, 2009 - 7:30AM-8:00AM
POSTER DISPLAY HOURS:	Monday May 18, 2009 - 8:00AM-8:00PM
POSTER AUTHOR DISCUSSION HOUR:	Monday May 18, 2009 - 6:00PM-7:00PM
DISMANTLE:	Monday May 18, 2009 - 8:00PM-8:30PM

HEALTH CARE INTERVENTIONS Clinical Outcomes Studies
PHC1	COMPARATIVE EFFECTIVENESS OF LOW INTENSITY PULSED ULTRASOUND VERSUS SHAM TREATMENT OF TIBIA FRACTURE IN PATIENTS WITH NONUNION: A DOUBLE-BLIND, MULTI-CENTER RANDOMIZED CONTROLLED TRIAL
	Schofer M¹, Schmelz A², Schultz M³
	¹University Hospital Giessen and Marburg, Marburg, Germany, ²University of Ulm, Ulm, Germany, ³Pharmaccess Inc, Westmount, QC, Canada

HEALTH CARE INTERVENTIONS Cost Studies
PHC2	SOCIOECONOMIC STATUS AND COST OF CARE IN THE ELDERLY UNDERGOING MAJOR ORTHOPEDIC SURGERY
	Baser O¹, Wang L², Gust C², Dysinger A²
	¹University of Michigan and STATinMED Research, Ann Arbor, MI, USA, ²STATinMED Research, Ann Arbor, MI, USA

PHC3	COST-EFFECTIVENESS ANALYSIS OF PIMOBENDAN COMPARED TO BENAZEPRIL FOR THE TREATMENT OF ACQUIRED MYXOMATOUS MITRAL VALVE DISEASE IN DOGS IN GERMANY
	Poulsen Nautrup B¹, Poulsen Nautrup C², Van Vlaenderen I³
	¹EAH Consulting, Juelich, Juelich, Northrhine Westf, Germany, ²Ludwig-Maximilians University Munich, Munich, Bavaria, Germany, ³Deloitte, Diegem, Diegem, Belgium

PHC4	COST-EFFECTIVENESS OF PIMOBENDAN VERSUS BENAZEPRIL IN ACQUIRED MYXOMATOUS MITRAL VALVE DISEASE IN DOGS: AN ADAPTATION TO SWITZERLAND
	Poulsen Nautrup B¹, Van Vlaenderen I²
	¹EAH Consulting, Juelich, Juelich, Northrhine Westf, Germany, ²Deloitte, Diegem, Diegem, Belgium

PHC5	CHOICE OF HEMOSTATIC AGENT AND HOSPITAL LENGTH OF STAY IN CARDIOVASCULAR SURGERY
	Krishnan S¹, Conner TM², Leslie RC², Stemkowski S³
	¹Baxter BioSurgery, Westlake Village, CA, USA, ²Outcomes Research Consulting, Austin, TX, USA, ³Premier Inc, Charlotte, NC, USA

HEALTH CARE INTERVENTIONSPatient-Reported Outcomes Studies
PHC6	SUBJECTS SUFFERING FROM HALITOSIS: IMPACTS OF THE TREATMENT
	Taieb C
	Pierre Fabre, Boulogne, France

PHC7	DEVELOPMENT AND VALIDATION OF SPECIFIC HEALTH RELATED QUALITY OF LIFE QUESTIONNAIRE FOR HALITOSIS: THE HALITOSIS QUALITY OF LIFE QUESTIONNAIRE (HQLQ)
	Taieb C¹, Maso H²
	¹Pierre Fabre, Boulogne, France, ²PFOC, CASTRES, France

HEALTH CARE INTERVENTIONS Health Care Use & Policy Studies
PHC8	REGIONAL DISPARITIES AND ECONOMIC OUTCOMES ASSOCIATED WITH MINIMALLY INVASIVE AND CONVENTIONAL SURGERIES OF THE CHEST, ABDOMEN, AND PELVIS
	Moore M¹, Hochheiser L², Gunnarsson C³, Ladapo J⁴, Borah B⁵
	¹Ethicon Endo-Surgery, Inc., Cincinnati, OH, USA, ²University of Vermont, Jackson, WY, USA, ³S2 Statistical Solutions, Inc, Cincinnati, OH, USA, ⁴Beth Israel Deaconess Medical Center, Boston, MA, USA, ⁵i3 Innovus, Eden Prairie, MN, USA

POSTER PRESENTATIONS SESSION I
SET-UP:	Monday May 18, 2009 - 7:30AM-8:00AM
POSTER DISPLAY HOURS:	Monday May 18, 2009 - 8:00AM-8:00PM
POSTER AUTHOR DISCUSSION HOUR:	Monday May 18, 2009 - 6:00PM-7:00PM
DISMANTLE:	Monday May 18, 2009 - 8:00PM-8:30PM

MUSCULAR-SKELETAL DISORDERS Clinical Outcomes Studies
PMS1	INCREASED STANDARDIZED MORTALITY RATIO IN WORKERS WITH PERMANENT OCCUPATIONAL DISABILITY OF LOWER LIMB: A FOLLOW-UP STUDY OF 21 YEARS
	Lin SH¹, Lee HY¹, Chang YY¹, Jang Y¹, Chen PC¹, Wang JD²
	¹National Taiwan University Hospital, Taipei, Taiwan, ²National Taiwan University, College of Public Health, Taipei, Taiwan

PMS2	GOUT AND THE RISK OF ACUTE MYOCARDIAL INFARCTION AMONG ELDERLY WOMEN
	De Vera MA¹, Rahman MM², Bhole V², Rankin J², Aghajanian J², Kopec J², Choi HK¹
	¹UBC School of Population & Public Health, Vancouver, BC, Canada, ²Arthritis Research Centre of Canada, Vancouver, BC, Canada

PMS3	COMPARISON OF 3 COMORBIDITY MEASURES AFFECTING PHYSICAL FUNCTION AND QUALITY OF LIFE FOR PATIENTS WITH ANKYLOSING SPONDYLITIS
	Gooch K¹, Wong R²
	¹Abbott Laboratories, Abbott Park, IL, USA, ²Abbott Laboratories, Parsippany, NJ, USA

PMS4	RISK FACTORS FOR INCIDENT GOUT AMONG WOMEN: A PROSPECTIVE STUDY
	Bhole V¹, De Vera MA², Rahman MM¹, Choi HK²
	¹Arthritis Research Centre of Canada, Vancouver, BC, Canada, ²UBC School of Population & Public Health, Vancouver, BC, Canada

PMS5	FACTORS INFLUENCING THE LENGTH OF STAY AND TOTAL CHARGES FOR PEDIATRIC PATIENTS DIAGNOSED WITH OSTEOMYELITIS
	Dorwart JL
	University of Louisville, Louisville, KY, USA

PMS6	DEVELOPMENT OF TESTS FOR DIAGNOSIS OF RHEUMATOID ARTHRITIS
	Schiff L¹, Foster T¹, Creeden J², Gartemann J², Hsieh J², Pashos CL¹
	¹Abt Bio-Pharma Solutions, Inc., Lexington, MA, USA, ²Roche Diagnostics, Ltd, Rotkreuz, Switzerland

PMS7	A 2-YEAR EVALUATION OF INFLIXIMAB'S EFFECTIVENESS IN THE TREATMENT OF RHEUMATOID ARTHRITIS IN ACTUAL PRACTICE
	Tang B¹, Rahman M², Naim A¹, Meissner B³, Dehoratius R¹, Piech CT¹
	¹Centocor Ortho Biotech Services, LLC, Horsham, PA, USA, ²Ortho Clinical Diagnostics, Raritan, NJ, USA, ³Xcenda, Palm Harbor, FL, USA

PMS8	BIOLOGIC THERAPY REDUCES PATIENT-REPORTED SEVERITY OF RHEUMATOID ARTHRITIS IN THE REAL WORLD SETTING
	Tang B¹, McKenzie RS¹, Freedman D², Wagner S², Piech CT¹
	¹Centocor Ortho Biotech Services, LLC, Horsham, PA, USA, ²Consumer Health Sciences International, Princeton, NJ, USA

PMS9	TREATING ARTHRITIS OF THE KNEE: THE IMPACT ON PAIN IN PATIENTS' EVERYDAY LIVES
	Taieb C
	Pierre Fabre, Boulogne, France

PMS10	DOSING PATTERNS FOR RHEUMATOID ARTHRITIS PATIENTS TREATED WITH ABATACEPT OR INFLIXIMAB
	Trivedi DN¹, Chapman RH², Smith D², Semroc G², Rosenblatt LC¹
	¹Bristol-Myers Squibb, Plainsboro, NJ, USA, ²IMS Health, Falls Church, VA, USA

PMS11	RELATIONSHIP BETWEEN LEVELS OF PHYSICAL ACTIVITY AT WORK AND PREVALENCE OF ARTHRITIS AMONG WORKING POPULATION
	Bali V, Khan N
	University of New Mexico, Albuquerque, NM, USA

PMS12	FIBROMYALGIA: RUSSIAN RHEUMATOLOGISTS' KNOWLEDGE
	Nasonov E¹, Le Lay K², Soldatov D³, Taieb C²
	¹Rheumatology Institute-Russian Federation, Moscou, Russia, ²Pierre Fabre, Boulogne, France, ³Pierre Fabre Laboratories, Moscou, Russia

PMS13	PREVALENCE OF FIBROMYALGIA IN RUSSIA
	Le Lay K¹, Nasonov E², Soldatov D³, Taieb C¹
	¹Pierre Fabre, Boulogne, France, ²Rheumatology Institute, Moscou, Russia, ³Pierre Fabre Laboratories, Moscou, Russia

PMS14	THE RELATIONSHIP BETWEEN SURGICAL DELAY OVER 24 HOURS AND 30 DAYS MORTALITY FOLLOWING FEMORAL NECK FRACTURE IN THE PRESENCE OF DIFFERENT CO-MORBIDITIES
	Sebestyén A¹, Boncz I², Molnár A¹, Kőrösi L³, Kriszbacher I⁴, Brodszky V⁵, Gulácsi L⁵, Sándor J²
	¹National Health Insurance Fund Administration, Budapest, Hungary, ²University of Pécs, Pécs, Hungary, ³National Health Insurance Fund Administration (OEP), Budapest, Hungary, ⁴University of Pécs, Pecs, Hungary, ⁵Corvinus University of Budapest, Budapest, Hungary

PMS15	RELATIONSHIP BETWEEN SURGICAL INTERVENTION TYPE AND 30 DAYS MORTALITY OF ELDERLY FEMORAL NECK FRACTURE IN THE PRSENCE OF DIFFERENT CO-MORBIDITIES
	Sebestyén A¹, Boncz I², Molnár A¹, Kőrösi L³, Kövi R³, Kriszbacher I⁴, Oláh A⁴, Pentek M⁵, Sándor J²
	¹National Health Insurance Fund Administration, Budapest, Hungary, ²University of Pécs, Pécs, Hungary, ³National Health Insurance Fund Administration (OEP), Budapest, Hungary, ⁴University of Pécs, Pecs, Hungary, ⁵Flor Ferenc County Hospital, Kistarcsa, Hungary

PMS16	ESTIMATION OF LIFE EXPECTANCIES AND LOSS OF LIFE EXPECTANCIES FOR WORKERS WITH PERMANENT OCCUPATIONAL DISABILITY OF UPPER AND LOWER LIMBS: A FOLLOW-UP STUDY OF 69,964 WORKERS FOR 21 YEARS
	Lin SH¹, Lee HY¹, Chang YY¹, Jang Y¹, Wang JD²
	¹National Taiwan University Hospital, Taipei, Taiwan, ²National Taiwan University, College of Public Health, Taipei, Taiwan

MUSCULAR-SKELETAL DISORDERSCost Studies
PMS17	NATIONAL COST OF ILLNESS STUDY COMPARING VETERAN PATIENTS WITH GOUT TO THOSE WITH DIFFICULT TO MANAGE GOUT
	Raisch DW¹, Campbell HM², Khan N³, Rice J²
	¹University of New Mexico College of Pharmacy, Albuquerque, NM, USA, ²Department of Veterans Affairs Cooperative Studies Program, Albuquerque, NM, USA, ³University of New Mexico, Albuquerque, NM, USA

PMS18	ESTIMATION OF COSTS RELATED TO ADVERSE EVENTS IN NSAID TREATMENT OF OSTEOARTHRITIS – A COMPARISON BETWEEN CELECOXIB AND IBUPROFEN USING A VALIDATED MODEL
	Svedbom A¹, Borgstrom F¹, Holmstrom S², Miltenburger C³
	¹i3 Innovus, Stockholm, Sweden, ²NicOx, Sophia Antipolis, France, ³i3 Innovus, Berlin, Germany

PMS19	DRUG UTILIZATION AND SPENDING TRENDS OF BISPHOSPHONATE MEDICATIONS MEDICAID PROGRAMS IN THE UNITED STATES
	Berry E¹, Guo JJ¹, Kelton CM¹, Shiyanbade H², Knight D³, Heaton PC¹
	¹University of Cincinnati, Cincinnati, OH, USA, ²university of Cincinnati, cincinnati, OH, USA, ³University of Cincinnati, cincinnati, OH, USA

PMS20	A COMPARISON OF DIFFERENT METHODS OF ESTIMATING FRACTURE RISK AND FRACTURE RISK REDUCTION IN COST-EFFECTIVENESS ANALYSES OF THE OSTEOPOROSIS TREATMENT BAZEDOXIFENE
	Borgström F¹, Coelho J², Ström O², McCloskey E³, Odén A⁴, Johansson H⁵, Kanis JA⁶
	¹i3 Innovus, Stockholm, Sweden, ²i3 Innovus, Stockholm, Stockholm, Sweden, ³Osteoporosis Centre, Sheffield, Sheffield, UK, ⁴University of Sheffield, Gothenbourg, Gothenbourg, Sweden, ⁵University of Sheffield, Gothenbourg, Gothebourg, Sweden, ⁶University of Sheffield, Sheffield, Sheffield, UK

PMS21	ECONOMIC EVALUATION OF THE USE OF HYLAN G-F 20 IN THE HANDLING OF SEVERE KNEE OSTEOARTHROSIS
	Salinas Escudero G¹, Idrovo J², Zapata L², Herrera Rodriguez G³
	¹Hospital Infantil de México Federico Gómez, México DF, Distrito Federal, Mexico, ²Guia Mark, Mexico, DF, Mexico, ³Genzyme, Mexico, DF, Mexico

PMS22	COST-EFFECTIVENESS OF THE USE OF ETANERCEPT VS. RITUXIMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS IN MEXICO
	Gao X¹, Hwang S², Carpiuc KT¹, Stephens JM¹, Sato R², Singh A², Rivera R³, García E³, Bierschwale H³
	¹PharMerit North America LLC, Bethesda, MD, USA, ²Wyeth Research, Collegeville, PA, USA, ³Wyeth Mexico, Naucalpan, Mexico, Mexico

PMS23	AN ECONOMIC ANALYSIS COMPARING THREE COMBINATIONS OF TUMOR NECROSIS FACTOR-ALPHA AGENTS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS
	Agarwal SJ, Sansgiry SS, Johnson ML
	University of Houston, Houston, TX, USA

PMS24	LOWER HIP FRACTURE RATES IN THE FIRST YEAR OF THERAPY TRANSLATE INTO FAVORABLE COST-EFFECTIVENESS FOR RISEDRONATE VS. GENERIC ALENDRONATE AMONG HIGH RISK PATIENTS
	Thompson MF¹, Pasquale MK², Grima DT¹
	¹Cornerstone Research Group Inc, Burlington, ON, Canada, ²Procter & Gamble Pharmaceuticals, Mason, OH, USA

PMS25	COST-EFFECTIVENESS IN OSTEOARTHRITIS PAIN RELIEF TREATMENT WITH NSAIDS – A DETERMINATION AND ESTIMATION OF KEY DRIVERS
	Svedbom A¹, Borgstrom F¹, Holmstrom S², Miltenburger C³
	¹i3 Innovus, Stockholm, Sweden, ²NicOx, Sophia Antipolis, France, ³i3 Innovus, Berlin, Germany

PMS26	CHARACTERISTICS AND HEALTH CARE UTILIZATION RESULTING FROM INJECTION SITE REACTIONS WITH ANTI-TNF TREATMENTS FOR RHEUMATOID ARTHRITIS: AN ANALYSIS OF CASES AT AN URBAN TEACHING HOSPITAL
	Pizzi LT¹, Abouzaid S¹, Naik M², Cobb N¹, Buchanan J³, Parasuraman S³, Derk CT²
	¹Jefferson School of Population Health, Philadelphia, PA, USA, ²Jefferson Medical College, Philadelphia, PA, USA, ³Johnson & Johnson Pharmaceutical Services LLC, Malvern, PA, USA

PMS27	COSTS OF PSORIATIC ARTHRITIS IN HUNGARY; RESULTS FROM A CROSS-SECTIONAL SURVEY
	Brodszky V¹, Becsi R¹, Karpati K¹, Pentek M², Sebestyen A³, Boncz I⁴, Gulacsi L¹
	¹Corvinus University of Budapest, Budapest, Hungary, ²Flor Ferenc County Hospital, Kistarcsa, Hungary, ³National Health Insurance Fund Administration, Pecs, Hungary, ⁴University of Pécs, Pécs, Hungary

PMS28	THE COSTS OF NON-VERTEBRAL OSTEOPOROTIC FRACTURES IN THE UNITED STATES
	Birnbaum HG¹, Pike C¹, Schiller M¹, Sharma H¹, Gu A¹, Burge RT², Edgell ET²
	¹Analysis Group, Inc., Boston, MA, USA, ²Eli Lilly and Company, Indianapolis, IN, USA

PMS29	GOLIMUMAB SIGNIFICANTLY REDUCES TIME LOST FROM WORK FOR PATIENTS WITH RHEUMATOID ARTHRITIS: POOLED RESULTS FROM THREE PHASE 3 STUDIES
	Buchanan J¹, Emery P², Keystone EC³, Smolen J⁴, Doyle MK⁵, Hsia EC⁵, Rahman MU⁵, Gathany T¹, Han C¹, Parasuraman S¹
	¹Johnson & Johnson Pharmaceutical Services LLC, Malvern, PA, USA, ²University of Leeds, Leeds, UK, ³University of Toronto/ Mount Sinai Hospital, Toronto, ON, Canada, ⁴Medical University of Vienna, Vienna, Austria, ⁵Centocor Research and Development, Inc./ U Penn Medical School, Malvern/ Philadelphia, PA, USA

PMS30	THE ECONOMIC CONSEQUENCES OF RHEUMATOID ARTHRITIS: ANALYSIS OF THE MEDICAL EXPENDITURE PANEL SURVEY (MEPS) 2005 AND 2006 DATA
	Simons WR¹, Chang CY¹, Trivedi DN², Rosenblatt LC²
	¹Global Health Economics & Outcomes Research, Inc, Summit, NJ, USA, ²Bristol-Myers Squibb, Plainsboro, NJ, USA

PMS31	CLINICAL AND ECONOMIC CHARACTERISTICS OF PATIENTS WITH FIBROMYALGIA
	Lachaine J¹, Beauchemin C¹, Landry PA²
	¹University of Montreal, Montreal, QC, Canada, ²Pfizer Canada Inc, Kirkland, QC, Canada

PMS32	HIGHER OUT-OF-POCKET PHARMACY EXPENSE IS ASSOCIATED WITH HIGHER SWITCHING RATES AMONG ANTI-TUMOR NECROSIS FACTOR IN PATIENTS WITH RHEUMATOID ARTHRITIS
	Tang B¹, Changolkar A², McKenzie RS¹, Piech CT¹
	¹Centocor Ortho Biotech Services, LLC, Horsham, PA, USA, ²SOAL PharmaTech Solutions, LLC, Philadelphia, PA, USA

PMS33	BURDEN OF ILLNESS OF CONSERVATIVE MEDICAL MANAGEMENT OF OSTEOPOROTIC VERTEBRAL COMPRESSION FRACTURES IN JAPAN
	Konno S¹, Togawa D², Kamae I³, Inoue S⁴, Kikuchi S¹
	¹Fukushima Medical University, Fukushima, Fukushima, Japan, ²Hakodate Central General Hospital, Hakodate, Hokkaido, Japan, ³Keio University Graduate School of Health Management, Fujisawa, Kanagawa, Japan, ⁴Crecon Research and Consulting Inc, Shibuya-ku, Tokyo, Japan

PMS34	AN EXPLORATORY EVALUATION OF THE COST-EFFECTIVENESS OF RITUXIMAB AND ABATACEPT IN THE TREATMENT OF MODERATE TO SEVERE RHEUMATOID ARTHRITIS AFTER AN INADEQUATE RESPONSE TO A TUMOUR NECROSIS FACTOR INHIBITOR IN CANADA
	Yunger S, Mistry B
	Hoffmann-La Roche, Mississauga, ON, Canada

PMS35	WITHDRAWN

MUSCULAR-SKELETAL DISORDERS Patient-Reported Outcomes Studies
PMS36	IMPACT OF A SUPPORT PROGRAM ON THE TREATMENT COMPLIANCE IN OSTEOPOROSIS PATIENTS
	Guzzo MR¹, Muranaka AH²
	¹Produtos Roche Químicos e Farmacêuticos SA, São Paulo, São Paulo, Brazil, ²Universidade Federal de São Paulo, Sao Paulo, SP, Brazil

PMS37	QUALITY OF LIFE AND COMPLIANCE IN GIRLS WITH ADOLESCENT IDIOPATHIC SCOLIOSIS
	Rivett L, Rothberg A
	University of the Witwatersrand Faculty of Health Sciences, Johannesburg, South Africa

PMS38	PATIENTS SUCCESS CRITERIA AND EXPECTATIONS IN FALLS REHABILITATION
	Romero S
	Department of Veterans Affairs, Gainesville, FL, USA

PMS39	IMPAIRMENTS IN QUALITY OF LIFE, DAILY FUNCTION, AND WORK PRODUCTIVITY AND ACTIVITY IN RHEUMATOID ARTHRITIS PATIENTS WHO USE SUBCUTANEOUS BIOLOGIC THERAPIES
	Tang B¹, Naim A¹, McKenzie RS¹, Bailey R², Freedman D³, Wagner S³, Piech CT¹
	¹Centocor Ortho Biotech Services, LLC, Horsham, PA, USA, ²Centocor Ortho Biotech Services, LLC, Horsham, NJ, USA, ³Consumer Health Sciences International, Princeton, NJ, USA

PMS40	UTILITY AND QUALITY OF LIFE OF PATIENTS WITH OSTEOARTHRITIS TREATED WITH THE CYCLOOXYGENASE INHIBITING NITRIC OXIDE DONATOR (CINOD) NAPROXCINOD
	Jonsson B¹, Pfister P², Holmstrom S³, Kobelt G⁴
	¹Uppsala University, Uppsala, Sweden, ²NicOx, Sophia Antipolis Cedex, France, ³NicOx, Sophia Antipolis, France, ⁴European Health Economics, Speracedes, France

PMS41	AN ASSESSMENT OF SELF REPORTED OUTCOMES IN A NATIONALLY REPRESENTATIVE SAMPLE OF ELDERLY PERSON DIAGNOSED WITH RHEUMATOID ARTHRITIS
	Rajpura JR
	St. John's University, Fresh Meadows, NY, USA

PMS42	THE EFFECT OF LIFESTYLE CHOICES ON THE RISK OF IMPAIRMENT IN RHEUMATOID ARTHRITIS PATIENTS: AN ANALYSIS OF AEROBIC EXERCISE AND CIGARETTE SMOKING
	Shah A¹, Plumb J¹, Brawer R¹, Tang B²
	¹Thomas Jefferson University, Philadelphia, PA, USA, ²Centocor Ortho Biotech, Inc, Horsham, PA, USA

PMS43	IS THE HEALTH UTILITIES INDEX VALID AND RESPONSIVE IN ASSESSING PATIENTS WITH ANKYLOSING SPONDYLITIS?
	Gooch K¹, Feeny DH², Wong R³, Pangan A¹, Revicki D⁴, van der Heijde D⁵
	¹Abbott Laboratories, Abbott Park, IL, USA, ²Kaiser Permanente Center for Health Research, Portland, OR, USA, ³Abbott Laboratories, Parsippany, NJ, USA, ⁴United BioSource Corporation, Bethesda, MD, USA, ⁵Leiden University Medical Center, Leiden, Netherlands

PMS44	VALIDATION OF THE MULTI-ATTRIBUTE HEALTH UTILITY (MAHU) DERIVED FROM A COMPUTER ADAPTIVE INSTRUMENT, CAT-5D-QOL, IN OSTEOARTHRITIS
	Kang W¹, Sayre EC², Steininger G¹, Doerfling P³, Ratzlaff C¹, Esdaile J³, Kopec J³
	¹University of British Columbia, Vancouver, BC, Canada, ²Arthritis Research Centre of Canada and Simon Fraser University, Vancouver, BC, Canada, ³Arthritis Research Centre of Canada, Vancouver, BC, Canada

PMS45	EXTENSION FROM INPATIENTS TO OUTPATIENTS: PERFORMANCE OF THE OXFORD KNEE SCORE IN MEASURING HEALTH OUTCOMES IN PATIENTS WITH KNEE OSTEOARTHRITIS
	Xie F¹, Ye H², Zhang Y³, Liu X², Lei T², Li SC⁴
	¹McMaster University, Hamilton, ON, Canada, ²Fudan University, Shanghai, China, ³Huashan Hospital, Shangai, China, ⁴University of Newcastle, Callaghan, Australia

PMS46	PHYSICAL ACTIVITY IN CANADIAN ADULTS WITH ARTHRITIS: A POPULATION-BASED STUDY
	De Vera MA¹, Bhole V², Ratzlaff C¹
	¹UBC School of Population & Public Health, Vancouver, BC, Canada, ²Arthritis Research Centre of Canada, Vancouver, BC, Canada

PMS47	GOLIMUMAB SIGNIFICANTLY IMPROVES PRODUCTIVITY IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS: RESULTS FROM THE PHASE 3 GO-RAISE STUDY
	Braun J¹, Inman RD², van der Heijde D³, Mack M⁴, Parasuraman S⁵, Buchanan J⁵, Hsu B⁴, Beutler A⁴, Han C⁵, Deodhar A⁶
	¹Rheumazentrum Ruhrgebiet, Herne, Germany, ²University of Toronto, Toronto, ON, Canada, ³Leiden University Medical Center, Leiden, Netherlands, ⁴Centocor Research and Development, Inc, Malvern, PA, USA, ⁵Johnson & Johnson Pharmaceutical Services LLC, Malvern, PA, USA, ⁶Oregon Health & Science University, Portland, OR, USA

PMS48	GOLIMUMAB, A HUMAN ANTI-TNF-ALPHA MONOCLONAL ANTIBODY, SIGNIFICANTLY IMPROVES SELF-REPORTED PRODUCTIVITY IN PATIENTS WITH RHEUMATOID ARTHRITIS: RESULTS FROM THREE PHASE 3 STUDIES
	Buchanan J¹, Fleischmann R², Genovese MC³, Kay J⁴, Hsia EC⁵, Doyle MK⁵, Rahman MU⁵, Han C¹, Parasuraman S¹
	¹Johnson & Johnson Pharmaceutical Services LLC, Malvern, PA, USA, ²Univeristy of Texas Southwestern Medical Center, Dallas, TX, USA, ³Stanford University, Palo Alto, CA, USA, ⁴Massachussetts General Hospital/ Harvard Medical School, Boston, MA, USA, ⁵Centocor Research and Development, Inc./ U Penn Medical School, Malvern/ Philadelphia, PA, USA

MUSCULAR-SKELETAL DISORDERS Health Care Use & Policy Studies
PMS49	DRUG COVERAGE, UTILIZATION AND HEALTH AMONG ELDERLY PATIENTS WITH ARTHRITIS
	Khan N
	University of New Mexico, Albuquerque, NM, USA

PMS50	A PRELIMINARY ANALYSIS OF BIOLOGICS MEDICATION-TAKING BEHAVIOR AMONG RHEUMATOID ARTHRITIS PATIENTS
	Miller K¹, Conner TM², Bunz TJ³, Wadsley CJ¹
	¹CIGNA, Greenwood Village, CO, USA, ²CIGNA, Austin, TX, USA, ³CIGNA, Bloomfield, CT, USA

PMS51	RETROSPECTIVE ANALYSIS OF INFLIXIMAB DOSING AND INFUSION PATTERNS IN PATIENTS WITH RHEUMATOID ARTHRITIS IN A COMMERCIALLY-INSURED POPULATION
	Carter C¹, Tang B¹, Changolkar A², McKenzie RS¹, Piech CT¹
	¹Centocor Ortho Biotech Services, LLC, Horsham, PA, USA, ²SOAL PharmaTech Solutions, LLC, Philadelphia, PA, USA

PMS52	NSAIDS CONSUMPTION IN CROATIA: THE EFFECTS OF PRICING POLICY CHANGES
	Vitezic D¹, Madjarevic T², Buble T³, Sestan B², Vitezic M², Mrsic Pelcic J⁴, Zupan G⁴
	¹University of Rijeka Medical School and University Hospital Centre Rijeka, Rijeka, Croatia, ²University Hospital for Orthopedic Surgery Lovran, Lovran, Croatia, ³Croatian National Health Insurance, Zagreb, Croatia, ⁴University of Rijeka Medical School, Rijeka, Croatia

PMS53	DISPARITIES IN MAJOR JOINT REPLACEMENT SURGERY AMONG ENROLLEES WITH AARP MEDICARE SUPPLEMENT INSURANCE
	Hawkins K¹, Escoto KH², Ozminkowski RJ³, Bhattarai GR⁴, Migliori RM⁵
	¹Ingenix, Brooklyn, MI, USA, ²Ingenix, Eden Prairie, MN, USA, ³UnitedHealth Group Alliances, Ann Arbor, MI, USA, ⁴Ingenix, Rocky Hill, CT, USA, ⁵UnitedHealth Group Alliances, MINNETONKA, MN, USA

PMS54	THE EFFECTS OF THE PART D DOUGHNUT HOLE ON MEDICARE PATIENTS WHO REQUIRE HIGH-COST MEDICATIONS
	Esposito D¹, Colby M², Ball DE³, Garavaglia SB⁴, Meadows E³, Marciniak MD³
	¹Mathematica Policy Research, Inc, Princeton, NJ, USA, ²Mathematica Policy Research, Inc, Washington, DC, USA, ³Eli Lilly and Company, Indianapolis, IN, USA, ⁴Medco Health Solutions, Inc., Franklin Lakes, NJ, USA

PMS55	RHEUMATOLOGIST INVOLVEMENT IN CARE OF PATIENTS WITH RHEUMATOID ARTHRITIS
	Trivedi DN, Kreilick C, Rosenblatt LC
	Bristol-Myers Squibb, Plainsboro, NJ, USA

PMS56	PHARMACY REFILL PATTERNS FOR SUBCUTANEOUS ANTI-TUMOR NECROSIS FACTOR AGENTS USED IN THE TREATMENT OF RHEUMATOID ARTHRITIS IN A MANAGED CARE SETTING
	Carter C¹, Tang B¹, Changolkar A², McKenzie RS¹, Piech CT¹
	¹Centocor Ortho Biotech Services, LLC, Horsham, PA, USA, ²SOAL PharmaTech Solutions, LLC, Philadelphia, PA, USA

PMS57	PRIMARY CARE VISITS IN RHEUMATOID ARTHRITIS PATIENTS RECEIVING INTRAVENOUS VERSUS SUBCUTAENOUS BIOLOGICS: A RETROSPECTIVE CLAIMS DATABASE STUDY
	Rosenblatt LC, Oza D
	Bristol-Myers Squibb, Plainsboro, NJ, USA

PMS58	FIBROMYALGIA: RUSSIAN RHEUMATOLOGISTS' DISEASE MANAGEMENT
	Nasonov E¹, Le Lay K², Soldatov D³, Taieb C²
	¹Rheumatology Institute-Russian Federation, Moscou, Russia, ²Pierre Fabre, Boulogne, France, ³Pierre Fabre Laboratories, Moscou, Russia

POSTER PRESENTATIONS SESSION I
SET-UP:	Monday May 18, 2009 - 7:30AM-8:00AM
POSTER DISPLAY HOURS:	Monday May 18, 2009 - 8:00AM-8:00PM
POSTER AUTHOR DISCUSSION HOUR:	Monday May 18, 2009 - 6:00PM-7:00PM
DISMANTLE:	Monday May 18, 2009 - 8:00PM-8:30PM

SENSORY SYSTEMS DISORDERS Clinical Outcomes Studies
PSS1	META-ANALYSIS OF BIOLOGIC THERAPIES FOR THE TREATMENT OF MODERATE TO SEVERE PSORIASIS
	Hawkins NS¹, Huntley A², Eaton J²
	¹Oxford Outcomes (UK), Oxford, UK, ²Oxford Outcomes (UK), Oxford, Oxfordshire, UK

PSS2	DISTRIBUTION OF PATHOGENS ASSOCIATED WITH ACUTE OTITIS MEDIA: A SYSTEMATIC REVIEW OF THE LITERATURE
	Pereira JA, Ismaila AS, Robson RC, Simpson SD
	GlaxoSmithKline, Mississauga, ON, Canada

PSS3	USING “NUMBER NEEDED TO TREAT” TO HELP CONCEPTUALIZE THE MAGNITUDE OF BENEFIT AND RISK OF TNFÁ INHIBITORS FOR PATIENTS WITH SEVERE PSORIASIS
	Warner J¹, Bhosle MJ², Balkrishnan R², Yentzer BA³, Feldman SR⁴
	¹Johns Hopkins University School of Medicine, Baltimore, MD, USA, ²Ohio State University, Columbus, OH, USA, ³Wake Forest University School of Medicine, Winston-Salem, NC, USA, ⁴Wake Forest University School of Medicine, Winston Salem, NC, USA

PSS4	WITHDRAWN

SENSORY SYSTEMS DISORDERSCost Studies
PSS5	A COST COMPARISON OF ADALIMUMAB AND ETANERCEPT FOR THE TREATMENT OF CHRONIC PLAQUE PSORIASIS IN THE UNITED KINGDOM
	Lebmeier M¹, Conway P², Warburton J¹
	¹Wyeth Pharmaceuticals, Maidenhead, UK, ²Wyeth Europa, Berkshire, UK

PSS6	AN ECONOMIC ANALYSIS TO EVALUATE ANTI-GLAUCOMA PHARMACOTHERAPY
	Bhowmik D, Sansgiry SS
	University of Houston, Houston, TX, USA

PSS7	A PHARMACOECONOMIC APPROACH OF THE USE OF INTRAVENOUS ANTIBIOTIC THERAPY FOR COMPLICATED SKIN AND SKIN-STRUCTURE INFECTIONS IN PUBLIC HEALTH CARE INSTITUTIONS IN MEXICO
	Soria-Cedillo IF¹, Baca-Muro VI², Martinez-Revelles M³, Jirash J³, De la Mora-Chávez T⁴, Garcia-Contreras F⁴
	¹Research Consulting, Hacienda Ojo de Agua, State of Mexico, Mexico, ²Research Consulting, Puebla, Puebla, Mexico, ³Novartis Farmaceutica Mexico, Mexico City, Mexico City, Mexico, ⁴Instituto Mexicano del Seguro Social, Mexico City, Mexico

PSS8	COST-EFFECTIVENESS STUDY OF COMPLICATED SKIN AND SKIN-STRUCTURE INFECTIONS TREATMENT IN PUBLIC HEALTH CARE INSTITUTIONS IN MEXICO
	Baca-Muro VI¹, Soria-Cedillo IF², Rosas R³, Martinez-Revelles M³, Olvera K³, Garcia-Contreras F⁴
	¹Research Consulting, Puebla, Puebla, Mexico, ²Research Consulting, Hacienda Ojo de Agua, State of Mexico, Mexico, ³Novartis Farmaceutica Mexico, Mexico City, Mexico City, Mexico, ⁴Instituto Mexicano del Seguro Social, Mexico City, Mexico

PSS9	REDUCTION OF ACUTE OTITIS MEDIA IN CHILDREN: A COST-CONSEQUENCE ANALYSIS OF THE NEW 10-VALENT PNEUMOCOCCAL NON-TYPEABLE HAEMOPHILUS INFLUENZAE PROTEIN-D CONJUGATE VACCINE (PHID-CV) COMPARED WITH THE 7-VALENT PNEUMOCOCCAL VACCINE (PCV-7)
	Pereira JA, Ismaila AS, Robson RC, Simpson SD
	GlaxoSmithKline, Mississauga, ON, Canada

PSS10	ECONOMIC BURDEN OF MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS IN CANADA
	Davie AM¹, Brazier NC², Tsao NW¹, Goring SM¹, Albrecht LE³, Gratton D⁴, Lynde C⁵, Jivraj F², Levy AR¹
	¹Oxford Outcomes Ltd, Vancouver, BC, Canada, ²Janssen-Ortho, Inc., Toronto, ON, Canada, ³Dr Lorne Albrecht Inc, Surrey, BC, Canada, ⁴Dr David Gratton International Dermatology Research Inc, Montréal, QC, Canada, ⁵Lynderm Research Inc, Markham, ON, Canada

PSS11	ECONOMIC BURDEN OF SEVERE CHRONIC HAND ECZEMA/DERMATITIS IN CANADIAN ADULTS
	Piwko C¹, Vicente C¹, Bereza BG², Ventin A³
	¹PIVINA Consulting Inc, Thornhill, ON, Canada, ²University of Toronto, Toronto, ON, Canada, ³Basilea Pharmaceuticals Corporation, Toronto, ON, Canada

PSS12	COST-UTILITY ANALYSIS OF POSTERIOR LAMELLAR KERATOPLASTY IN CANADA
	Beauchemin C¹, Brunette I², Lachaine J¹
	¹University of Montreal, Montreal, QC, Canada, ²Maisonneuve-Rosemont Hospital, Montreal, QC, Canada

PSS13	OUTCOMES OF CATARACT PATIENTS WITH ASTIGMATISM: IMPLANTATION OF TORIC VERSUS CONVENTIONAL MONOFOCAL INTRAOCULAR LENS
	Denevich S¹, Lee WC², Waycaster C³, Pennie S², Ganz M⁴, Pashos CL¹
	¹Abt Bio-Pharma Solutions, Inc., Lexington, MA, USA, ²Abt Bio-Pharma Solutions, Inc., Bethesda, MD, USA, ³Alcon Laboratories Inc, Fort Worth, TX, USA, ⁴Abt Bio-Pharma Solutions, Inc. and Harvard School of Public Health, Lexington, MA, USA

PSS14	HEALTH RESOURCE USE DURING STAPLE REMOVAL FOLLOWING GRAFT FIXATION
	Krishnan S¹, Foster KN², Conner TM³, Abrams SZ⁴
	¹Baxter BioSurgery, Westlake Village, CA, USA, ²Maricopa Medical Center, Phoenix, AZ, USA, ³Outcomes Research Consulting, Austin, TX, USA, ⁴Baxter Healthcare Corporation, Westlake Village, CA, USA

SENSORY SYSTEMS DISORDERSPatient-Reported Outcomes Studies
PSS15	CHANGES IN HEALTH RELATED UTILITY AMONG ADULTS WITH ATOPIC DERMATITIS TREATED WITH TACROLIMUS OINTMENT COMPARED TO A STANDARD CORTICOSTEROID REGIMEN
	Poole CD¹, Chambers C², Allsopp R², Currie CJ³
	¹Pharmatelligence, Cardiff, South Glamorgan, UK, ²Astellas Pharma Europe Ltd, Staines, Middlesex, UK, ³Cardiff University, Cardiff, UK

PSS16	CHARACTERIZING FUNCTIONAL LIMITATIONS FOR ADULTS WITH DIABETIC RETINOPATHY
	Szabo SM¹, Pleil A², Beusterien KM³, Wirostko B⁴, Potter MJ⁵, Tildesley H⁶, Levy AR¹
	¹Oxford Outcomes Ltd, Vancouver, BC, Canada, ²Pfizer, San Diego, CA, USA, ³Oxford Outcomes Ltd, Bethesda, MD, USA, ⁴Pfizer, New York, NY, USA, ⁵University of British Columbia, Vancouver, BC, Canada, ⁶Endocrine Research Inc, Vancouver, BC, Canada

PSS17	THE RELATIONSHIP OF DRIVING, VISION, AND QUALITY OF LIFE OF PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NV-ARMD)
	Payakachat N¹, Pleil A², Summers KH³
	¹University of Arkansas for Medical Sciences, Little Rock, AR, USA, ²Pfizer, San Diego, CA, USA, ³Purdue University, West Lafayette, IN, USA

PSS18	LINGUISTIC VALIDATION OF THE ATTENTION AND PERFORMANCE SELF-ASSESSMENT SCALE, APSA, FOR USE IN INTERNATIONAL STUDIES
	Montigny C¹, Görtelmeyer FR², Korbel US²
	¹Mapi Research Institute, Lyon, France, ²MERZ Pharmaceuticals GmbH, Frankfurt am Main, Germany

PSS19	DEVELOPMENT AND VALIDATION OF PATIENT-REPORTED OUTCOMES (PRO) TOOL FOR EYELASH CHARACTERISTICS
	Hammond GC¹, Burgess SM², Cole JC¹, Yang M¹, Hansen JE², Walt JG²
	¹QualityMetric Health Outcome Solutions, Lincoln, RI, USA, ²Allergan, Inc., Irvine, CA, USA

PSS20	THE RELATIONSHIP BETWEEN SATISFACTION WITH VISION AND SPECTACLE INDEPENDENCE
	Waycaster C
	Alcon Laboratories Inc, Fort Worth, TX, USA

PSS21	DISEASE BURDEN AND PRODUCTIVITY LOSS IN A CANADIAN ONLINE SURVEY POPULATION OF INDIVIDUALS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS
	Papp K¹, Wasel N², Poulin Y³, Chan D⁴, Fraquelli E⁴, Andrew R⁴
	¹K. Papp Clinical Research, Probity Medical Research, Waterloo, ON, Canada, ²Stratica Medical, Edmonton, AB, Canada, ³Laval University and Centre Dermatologique du Quebec Metropolitain, Quebec City, QC, Canada, ⁴Janssen-Ortho, Inc., Toronto, ON, Canada

SENSORY SYSTEMS DISORDERS Health Care Use & Policy Studies
PSS22	WITHDRAWN

PSS23	PHYSICIANS' AWARENESS, ATTITUDE, AND BEHAVIOR TO USE THE WAIT AND WATCH APPROACH FOR THE TREATMENT OF ACUTE OTITIS MEDIA
	Donga PZ¹, Goyal RK², Sansgiry SS²
	¹Abt Bio-Pharma Solutions, Inc., Lexington, MA, USA, ²University of Houston, Houston, TX, USA

POSTER PRESENTATIONS SESSION I
SET-UP:	Monday May 18, 2009 - 7:30AM-8:00AM
POSTER DISPLAY HOURS:	Monday May 18, 2009 - 8:00AM-8:00PM
POSTER AUTHOR DISCUSSION HOUR:	Monday May 18, 2009 - 6:00PM-7:00PM
DISMANTLE:	Monday May 18, 2009 - 8:00PM-8:30PM

HEALTH CARE DECISION-MAKER’S CASE STUDIES

PCASE1:	CASE STUDY OF CREATING A FORMULARY MANAGEMENT PROCESS AT A COMPREHENSIVE CANCER CENTER IN BANGALORE, INDIA
	Hariharaputhran D¹, Ajai Kumar B¹, Lal LS²
	¹Bangalore Institute of Oncology, HCG Enterprises Ltd, Bangalore, Karnataka, India, ²University of Texas MD Anderson Cancer Center, Houston, TX, USA

PCASE2:	THE HOSPITAL AS IMPORTANT SOURCE OF INFORMATION REGARDING CHARACTERISTICS OF HEALTH CARE USERS
	Figueira CMG, Serrano E, Sena E
	Vila Velha Hospital, Vila Velha, Espirito Santo, Brazil

PCASE3:	HTA PROCEDURES IN DRUG REIMBURSEMENT PROCESS IN POLAND. EVOLUTION OF RECOGNITION THE ROLE OF AGENCY OF HEALTH TECHNOLOGY ASSESSMENT (AHTAPOL) BY POLICY MAKERS
	Krol ZJ, Matusewicz W, Musialowicz A
	Agency for Health Technology Assessment, Warsaw, Poland

PCASE4:	THE EVALUATION PROCESS OF A REGIONAL DRUG AND THERAPEUTIC COMMITTEE IN ITALY: THE EXAMPLE OF NEW INDICATIONS FOR BEVACIZUMAB
	Scroccaro G¹, Venturini F², Alberti C², Visentin E², Berardo F², Paccagnella A³
	¹Azienda Ospedaliera di Verona, Verona, Italy, ²Veneto Regional Drug Information Center, Verona, Italy, ³ULSS 12 Veneziana, Venezia, Italy